155213-67-5 | 2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-

Packsize	Purity	Availability	Price	Discounted Price
250mg	98%	in stock	$20.00	$14.00
500mg	98%	in stock	$30.00	$21.00
1g	98%	in stock	$40.00	$28.00
25g	98%	in stock	$985.00	$690.00

Description

• Catalog Number: AA77206
• Chemical Name: 2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-
• CAS Number: 155213-67-5
• Molecular Formula: C37H48N6O5S2
• Molecular Weight: 720.9442
• MDL Number: MFCD00927142
• SMILES: O=C(N[C@H]([C@H](C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1

Computed Properties

• Complexity: 1040
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 50
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 18
• XLogP3: 6

Literature

• Encapsulation of ritonavir in solid lipid nanoparticles: in-vitro anti-HIV-1 activity using lentiviral particles.

  The Journal of pharmacy and pharmacology 20170801

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• Combined Docking and Quantum Chemical Study on CYP-Mediated Metabolism of Estrogens in Man.

  Chemical research in toxicology 20170220

• A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.

  eLife 20170101

• Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats.

  Chemico-biological interactions 20161125

• Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.

  Chemico-biological interactions 20160805

• Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.

  Drugs 20160801

• New combination antiviral for the treatment of hepatitis C.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20160715

• Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review.

  Expert review of anti-infective therapy 20160101

• Transactivation Assays to Assess Canine and Rodent Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) Activation.

  PloS one 20160101

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.

  The Annals of pharmacotherapy 20150501

• An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

  Canadian journal of gastroenterology & hepatology 20150101

• Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.

  BMC gastroenterology 20150101

• Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.

  Molecular pharmacology 20141201

• Pharmacokinetic enhancers in HIV therapeutics.

  Clinical pharmacokinetics 20141001

• Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.

  Journal of medicinal chemistry 20140612

• Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.

  Cancer chemotherapy and pharmacology 20140401

• Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.

  Bioorganic & medicinal chemistry letters 20140201

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

  Chemistry & biology 20130919

• Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.

  Biochemistry 20130702

• Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

  AIDS research and human retroviruses 20130501

• GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20130501

• Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.

  Bioorganic & medicinal chemistry 20130401

• [Cushing's syndrome during HIV treatment: pharmacological interaction during use of ritonavir].

  Nederlands tijdschrift voor geneeskunde 20130101

• LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions.

  Retrovirology 20130101

• Effect of HIV protease inhibitors on New World Leishmania.

  Parasitology international 20121201

• Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.

  Leukemia & lymphoma 20121201

• Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.

  Proteins 20121201

• Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.

  The Journal of infectious diseases 20121115

• Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.

  AIDS (London, England) 20121113

• Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.

  Journal of clinical pharmacology 20121101

• Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.

  British journal of clinical pharmacology 20121101

• [Cardiovascular risk in human immunodeficiency virus-infected patients in Spain. CoRIS cohort, 2011].

  Enfermedades infecciosas y microbiologia clinica 20121101

• Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.

  The Journal of antimicrobial chemotherapy 20121101

• Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

  Clinical pharmacology and therapeutics 20121101

• The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes.

  AIDS (London, England) 20121023

• Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study.

  AIDS research and human retroviruses 20121001

• Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.

  Phytotherapy research : PTR 20121001

• Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

  AIDS research and human retroviruses 20121001

• A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

  AIDS research and human retroviruses 20121001

• A population pharmacokinetic-pharmacogenetic analysis of atazanavir.

  AIDS research and human retroviruses 20121001

• Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20121001

• Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.

  The Journal of antimicrobial chemotherapy 20121001

• Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20121001

• Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro.

  Antiviral research 20121001

• Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.

  The Journal of infectious diseases 20121001

• Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France.

  Drug safety 20121001

• Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.

  Health affairs (Project Hope) 20121001

• Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.

  AIDS (London, England) 20120924

• Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.

  AIDS (London, England) 20120910

• Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor.

  AIDS (London, England) 20120910

• Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.

  HIV medicine 20120901

• Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.

  The Journal of antimicrobial chemotherapy 20120901

• Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120901

• Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

  Journal of acquired immune deficiency syndromes (1999) 20120901

• Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.

  Medecine et maladies infectieuses 20120901

• Quantized water access to the HIV-1 protease active site as a proposed mechanism for cooperative mutations in drug affinity.

  Biochemistry 20120821

• In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

  Chemical research in toxicology 20120820

• Impact of food administration on lopinavir-ritonavir bioequivalence studies.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120815

• Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.

  Journal of clinical pharmacology 20120801

• Significant interaction of tacrolimus with ritonavir during allogeneic hematopoietic SCT in an HIV-infected patient.

  Bone marrow transplantation 20120801

• Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20120801

• Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120801

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.

  Hepatology (Baltimore, Md.) 20120801

• The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

  HIV medicine 20120801

• Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120801

• Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS.

  Journal of chromatographic science 20120801

• Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20120801

• The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

  Virus research 20120801

• Microemulsions for oral administration and their therapeutic applications.

  Expert opinion on drug delivery 20120801

• Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.

  AIDS patient care and STDs 20120801

• Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20120801

• [A single tablet against HIV: new combination preparation improves therapy].

  Deutsche medizinische Wochenschrift (1946) 20120801

• Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.

  AIDS (London, England) 20120731

• Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

  AIDS (London, England) 20120717

• Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

  AIDS (London, England) 20120717

• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

  AIDS (London, England) 20120717

• Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

  The Cochrane database of systematic reviews 20120711

• Nevirapine-based therapy after suppression: can we switch?

  The Lancet. Infectious diseases 20120701

• Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

  The Lancet. Infectious diseases 20120701

• Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.

  The Journal of antimicrobial chemotherapy 20120701

• Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV).

  Intensive care medicine 20120701

• 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.

  International journal of oncology 20120701

• Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Untreated HIV infection is associated with higher blood alcohol levels.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.

  Antimicrobial agents and chemotherapy 20120701

• Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome.

  The American journal of the medical sciences 20120701

• Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.

  Antiviral research 20120701

• Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.

  Clinical pharmacokinetics 20120701

• HIV-2 encephalitis: case report and literature review.

  AIDS patient care and STDs 20120701

• Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans.

  Canadian journal of microbiology 20120701

• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

  The Lancet. Infectious diseases 20120701

• Cushing's syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection.

  International journal of STD & AIDS 20120701

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.

  Lancet (London, England) 20120630

• Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

  The New England journal of medicine 20120621

• Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.

  Drugs 20120618

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.

  Journal of clinical pharmacology 20120601

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Efficacy and safety outcomes among treatment-experienced women and men treated with etravirine in gender, race and clinical experience.

  AIDS research and human retroviruses 20120601

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Protease inhibitor monotherapy: what is its role?

  Current HIV/AIDS reports 20120601

• HIV therapies and the kidney: some good, some not so good?

  Current HIV/AIDS reports 20120601

• Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.

  Antimicrobial agents and chemotherapy 20120601

• Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.

  The Journal of antimicrobial chemotherapy 20120601

• Metabolic switching of BILR 355 in the presence of ritonavir. I. Identifying an unexpected disproportionate human metabolite.

  Drug metabolism and disposition: the biological fate of chemicals 20120601

• Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase.

  Drug metabolism and disposition: the biological fate of chemicals 20120601

• Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

  The Journal of antimicrobial chemotherapy 20120601

• Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

  The Journal of antimicrobial chemotherapy 20120601

• Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.

  International journal of clinical pharmacology and therapeutics 20120601

• Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.

  ChemMedChem 20120601

• Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.

  Expert opinion on pharmacotherapy 20120601

• Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

  Enfermedades infecciosas y microbiologia clinica 20120601

• Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

  PLoS medicine 20120601

• A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.

  PLoS pathogens 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy.

  Blood 20120517

• Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity.

  AIDS (London, England) 20120515

• HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges.

  AIDS (London, England) 20120515

• Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

  British journal of clinical pharmacology 20120501

• Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

  Scandinavian journal of infectious diseases 20120501

• Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20120501

• Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

  AIDS patient care and STDs 20120501

• Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120501

• Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.

  Clinical pharmacology and therapeutics 20120501

• Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.

  IUBMB life 20120501

• Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.

  Bioorganic & medicinal chemistry letters 20120501

• Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.

  Biopharmaceutics & drug disposition 20120501

• Is there a drug-drug interaction between darunavir/ritonavir and raltegravir?

  Journal of acquired immune deficiency syndromes (1999) 20120501

• Alternaria fungus induces the production of GM-CSF, interleukin-6 and interleukin-8 and calcium signaling in human airway epithelium through protease-activated receptor 2.

  International archives of allergy and immunology 20120501

• The impact of AT1002 on the delivery of ritonavir in the presence of bioadhesive polymer, carrageenan.

  Archives of pharmacal research 20120501

• Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency.

  International journal of STD & AIDS 20120501

• Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

  AIDS (London, England) 20120424

• Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.

  Journal of acquired immune deficiency syndromes (1999) 20120415

• Interaction of human cytochrome P4503A4 with ritonavir analogs.

  Archives of biochemistry and biophysics 20120415

• Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.

  Journal of clinical pharmacology 20120401

• [Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].

  Enfermedades infecciosas y microbiologia clinica 20120401

• Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.

  HIV medicine 20120401

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• Association of nephrotic syndrome with immune reconstitution inflammatory syndrome.

  Pediatric nephrology (Berlin, Germany) 20120401

• Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

  The Journal of antimicrobial chemotherapy 20120401

• Atazanavir: in pediatric patients with HIV-1 infection.

  Paediatric drugs 20120401

• Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.

  Urology 20120401

• HIV exposure through contact with body fluids.

  Prescrire international 20120401

• Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.

  Science China. Life sciences 20120401

• Nanotechnology and the treatment of HIV infection.

  Viruses 20120401

• Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

  AIDS (London, England) 20120327

• Virtual drug screen schema based on multiview similarity integration and ranking aggregation.

  Journal of chemical information and modeling 20120326

• Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20120322

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.

  AIDS (London, England) 20120313

• Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.

  AIDS (London, England) 20120313

• From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

  Journal of clinical pharmacology 20120301

• Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.

  The Journal of antimicrobial chemotherapy 20120301

• Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

  The Journal of antimicrobial chemotherapy 20120301

• Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

  The Journal of antimicrobial chemotherapy 20120301

• Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors.

  Journal of acquired immune deficiency syndromes (1999) 20120301

• Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.

  Applied health economics and health policy 20120301

• Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

  Expert opinion on investigational drugs 20120301

• Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20120301

• Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors.

  Current HIV research 20120301

• Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

  Current HIV research 20120301

• LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs.

  PLoS pathogens 20120301

• Drug-drug interaction analysis of pyronaridine/artesunate and ritonavir in healthy volunteers.

  The American journal of tropical medicine and hygiene 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• Perinatal lopinavir + ritonavir: adrenal insufficiency.

  Prescrire international 20120301

• Iatrogenic Cushing syndrome after epidural steroid injections for lumbar radiculopathy in an HIV-infected patient treated with ritonavir: a case report highlighting drug interactions for spine interventionalists.

  PM & R : the journal of injury, function, and rehabilitation 20120301

• CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.

  PLoS medicine 20120301

• Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa.

  International journal of STD & AIDS 20120301

• Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir/ritonavir, with or without nucleoside analogues.

  International journal of STD & AIDS 20120301

• Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.

  International journal of STD & AIDS 20120301

• Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.

  Indian journal of endocrinology and metabolism 20120301

• Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

  AIDS (London, England) 20120220

• Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.

  AIDS (London, England) 20120220

• Experimental and computational active site mapping as a starting point to fragment-based lead discovery.

  ChemMedChem 20120206

• Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

  Journal of clinical pharmacy and therapeutics 20120201

• Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.

  AIDS research and human retroviruses 20120201

• Correlation between HIV disease and lipid metabolism in antiretroviral-naïve HIV-infected patients in Japan.

  Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20120201

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.

  Pharmacological research 20120201

• Interpretation of genotypic resistance to predict darunavir/ritonavir failure in antiretroviral experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20120201

• Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120201

• Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.

  Journal of acquired immune deficiency syndromes (1999) 20120201

• Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

  The Journal of antimicrobial chemotherapy 20120201

• The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.

  Journal of enzyme inhibition and medicinal chemistry 20120201

• Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.

  Clinical pharmacology and therapeutics 20120201

• Re: Retinal pigment epitheliopathy, macular telangiectasis, and intraretinal crystal deposits in HIV-positive patients receiving ritonavir.

  Retina (Philadelphia, Pa.) 20120201

• Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.

  AIDS (London, England) 20120128

• Pharmacokinetic concerns related to the AIDS Clinical Trial Group (ACTG) A5262 trial.

  AIDS (London, England) 20120128

• A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120115

• Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir.

  Biochemical and biophysical research communications 20120106

• Interaction of calf thymus DNA with the antiviral drug Lamivudine.

  DNA and cell biology 20120101

• Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.

  Scandinavian journal of infectious diseases 20120101

• A comparative evaluation of mono-, di- and triglyceride of medium chain fatty acids by lipid/surfactant/water phase diagram, solubility determination and dispersion testing for application in pharmaceutical dosage form development.

  Pharmaceutical research 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Antiretroviral therapy initiation in France: adherence to national guidelines and outcome.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20120101

• A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.

  Journal of acquired immune deficiency syndromes (1999) 20120101

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.

  Journal of acquired immune deficiency syndromes (1999) 20120101

• Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries.

  Biochemistry research international 20120101

• Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

  Expert review of anti-infective therapy 20120101

• The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

  The Journal of infectious diseases 20120101

• Recent HIV-1 infection: to treat or not to treat, that is the question.

  The Journal of infectious diseases 20120101

• The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines.

  Experimental diabetes research 20120101

• First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.

  The American journal of tropical medicine and hygiene 20120101

• Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

  PloS one 20120101

• Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.

  PloS one 20120101

• HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients.

  BMC infectious diseases 20120101

• Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

  Antiviral therapy 20120101

• Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.

  Antiviral therapy 20120101

• Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

  BMC infectious diseases 20120101

• Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.

  Clinical interventions in aging 20120101

• Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

  PloS one 20120101

• Quality of Life among Persons with HIV/AIDS in Iran: Internal Reliability and Validity of an International Instrument and Associated Factors.

  AIDS research and treatment 20120101

• Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.

  Antiviral therapy 20120101

• Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

  Antiviral therapy 20120101

• Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.

  Antiviral therapy 20120101

• Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner.

  Antiviral therapy 20120101

• Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

  Core evidence 20120101

• Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

  BMC infectious diseases 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

  PloS one 20120101

• Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation.

  International journal of nanomedicine 20120101

• Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.

  BMC gastroenterology 20120101

• Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.

  International journal of STD & AIDS 20120101

• A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans.

  Malaria journal 20120101

• Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States.

  PloS one 20120101

• Spillover adherence effects of fixed-dose combination HIV therapy.

  Patient preference and adherence 20120101

• Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure.

  AIDS research and therapy 20120101

• The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.

  PloS one 20120101

• Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

  Clinical Medicine Insights. Cardiology 20120101

• Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa.

  AIDS research and treatment 20120101

• Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

  Retrovirology 20120101

• Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

  Clinical & developmental immunology 20120101

• Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles.

  PloS one 20120101

• Palatal Actinomycosis and Kaposi Sarcoma in an HIV-Infected Subject with Disseminated Mycobacterium avium-intracellulare Infection.

  Case reports in medicine 20120101

• HIV RNA suppression and immune restoration: can we do better?

  Clinical & developmental immunology 20120101

• Current status of new anticoagulants in the management of venous thromboembolism.

  Advances in hematology 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

  PloS one 20120101

• Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.

  HIV clinical trials 20120101

• Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings.

  Patient preference and adherence 20120101

• The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review.

  Patient preference and adherence 20120101

• Novel therapies for aggressive B-cell lymphoma.

  Advances in hematology 20120101

• Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

  AIDS research and treatment 20120101

• Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases.

  Malaria journal 20120101

• Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.

  Therapeutics and clinical risk management 20120101

• Effect of a New Prokinetic Agent DA-9701 Formulated with Corydalis Tuber and Pharbitidis Semen on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment.

  Clinical & developmental immunology 20120101

• An overview of the evidence and mechanisms of herb-drug interactions.

  Frontiers in pharmacology 20120101

• Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.

  Journal of medical economics 20120101

• Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.

  PloS one 20120101

• Sudden death of cardiac origin and psychotropic drugs.

  Frontiers in pharmacology 20120101

• A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

  HIV clinical trials 20120101

• Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors.

  HIV clinical trials 20120101

• Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.

  HIV clinical trials 20120101

• Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.

  AIDS research and treatment 20120101

• Impact of hepatitis C co-infection on response to antiretroviral treatment.

  AIDS reviews 20120101

• Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.

  PloS one 20120101

• Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups.

  Case reports in medicine 20120101

• Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

  International journal of nanomedicine 20120101

• Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.

  PloS one 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required.

  Mediterranean journal of hematology and infectious diseases 20120101

• Malaria and hiv in adults: when the parasite runs into the virus.

  Mediterranean journal of hematology and infectious diseases 20120101

• Inhaled corticosteroids in persons with HIV infection: not that harmless.

  Acta clinica Belgica 20120101

• Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era.

  Patient preference and adherence 20120101

• Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.

  BMC pediatrics 20120101

• Paying more than lip service to an oral lesion: a case of plasmablastic lymphoma.

  BMJ case reports 20120101

• Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment.

  AIDS reviews 20120101

• A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

  HIV clinical trials 20120101

• Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.

  BMC infectious diseases 20120101

• Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

  Antiviral therapy 20120101

• Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE.

  Journal of the National Medical Association 20120101

• Metabolomic screening and identification of the bioactivation pathways of ritonavir.

  Chemical research in toxicology 20111219

• Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.

  Biochemical and biophysical research communications 20111216

• Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20111215

• Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?

  Journal of acquired immune deficiency syndromes (1999) 20111215

• Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.

  Nanotoxicology 20111201

• Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

  Journal of clinical pharmacology 20111201

• Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

  British journal of clinical pharmacology 20111201

• Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.

  Alcoholism, clinical and experimental research 20111201

• Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

  Journal of acquired immune deficiency syndromes (1999) 20111201

• Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20111201

• Synthesis and antimycobacterial activity of novel amino alcohols containing central core of the anti-HIV drugs lopinavir and ritonavir.

  Chemical biology & drug design 20111201

• Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada.

  Pharmacoepidemiology and drug safety 20111201

• Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

  Journal of pharmacokinetics and pharmacodynamics 20111201

• HIV protease inhibitors induce metabolic dysfunction in part via increased JNK1/2 pro-inflammatory signaling in L6 cells.

  Antiviral research 20111201

• Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.

  The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20111201

• A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.

  International journal of clinical practice 20111201

• Pulmonary arterial hypertension: an update.

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20111201

• Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.

  Therapeutic drug monitoring 20111201

• HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin.

  Expert review of anti-infective therapy 20111201

• Protease inhibitor-associated QT interval prolongation.

  The Annals of pharmacotherapy 20111201

• Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.

  Gut and liver 20111201

• Diagnosis & treatment of tuberculosis in HIV co-infected patients.

  The Indian journal of medical research 20111201

• Paediatric HIV--trends & challenges.

  The Indian journal of medical research 20111201

• [Ergotism secondary to ergotamine-ritonavir association. Report of three cases].

  Revista medica de Chile 20111201

• Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

  International journal of pharmaceutics 20111128

• Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

  AIDS (London, England) 20111128

• Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.

  AIDS (London, England) 20111128

• Ritonavir stimulates foam cell formation by activating PKC.

  Chemico-biological interactions 20111115

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

  AIDS (London, England) 20111113

• Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

  Journal of clinical pharmacology 20111101

• Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.

  Journal of hepatology 20111101

• Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.

  Metabolism: clinical and experimental 20111101

• Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20111101

• Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.

  AIDS care 20111101

• Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

  The Pediatric infectious disease journal 20111101

• Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future.

  Metabolism: clinical and experimental 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

  The Journal of antimicrobial chemotherapy 20111101

• Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.

  Clinical pharmacology and therapeutics 20111101

• Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

  Clinical pharmacokinetics 20111101

• Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111101

• High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.

  AIDS (London, England) 20111023

• Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

  The Journal of infectious diseases 20111015

• A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20111015

• Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.

  AIDS research and human retroviruses 20111001

• Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

  HIV medicine 20111001

• Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20111001

• Kinetic characterization of rat hepatic uptake of 16 actively transported drugs.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?

  Journal of medical virology 20111001

• Inhaled fluticasone causes iatrogenic cushing's syndrome in patients treated with Ritonavir.

  The Journal of asthma : official journal of the Association for the Care of Asthma 20111001

• HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

  The Lancet. Infectious diseases 20111001

• Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.

  Therapeutic drug monitoring 20111001

• Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.

  The Pediatric infectious disease journal 20111001

• Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy.

  Journal of the American Academy of Dermatology 20111001

• Lopinavir + ritonavir oral solution: dangerous form for newborns.

  Prescrire international 20111001

• [Vitamin D and drugs].

  Medizinische Monatsschrift fur Pharmazeuten 20111001

• Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.

  Clinical therapeutics 20111001

• Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

  PLoS pathogens 20111001

• Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.

  AIDS (London, England) 20110924

• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  Annals of internal medicine 20110920

• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  Annals of internal medicine 20110920

• [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].

  Medicina clinica 20110910

• Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

  AIDS research and human retroviruses 20110901

• A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

  AIDS care 20110901

• Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

  The Journal of antimicrobial chemotherapy 20110901

• Renal excretion of apricitabine in rats: ex vivo and in vivo studies.

  European journal of drug metabolism and pharmacokinetics 20110901

• Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.

  AIDS patient care and STDs 20110901

• [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis].

  Medecine et maladies infectieuses 20110901

• Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders.

  PLoS pathogens 20110901

• Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

  Hematology reports 20110831

• Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.

  AIDS (London, England) 20110824

• Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.

  AIDS (London, England) 20110824

• Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110815

• Medication-based urolithiasis and atazanavir.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20110809

• Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.

  British journal of cancer 20110809

• Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons.

  AIDS research and human retroviruses 20110801

• Evaluation of antifungal activity of medicinal plant extracts against oral Candida albicans and proteinases.

  Mycopathologia 20110801

• Macrophage endocytic trafficking of antiretroviral nanoparticles.

  Nanomedicine (London, England) 20110801

• Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

  The Pediatric infectious disease journal 20110801

• Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors.

  Arthritis and rheumatism 20110801

• Ritonavir-boosted protease inhibitors in HIV therapy.

  Annals of medicine 20110801

• Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.

  Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 20110801

• 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

  The Journal of antimicrobial chemotherapy 20110801

• Efficacy of lopinavir-ritonavir reduced dose in HIV-infected patients.

  AIDS patient care and STDs 20110801

• Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study).

  HIV medicine 20110801

• CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

  Therapeutic drug monitoring 20110801

• UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

• Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

  AIDS (London, England) 20110731

• Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.

  The Journal of biological chemistry 20110715

• Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

  JAMA 20110706

• Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

  Journal of clinical pharmacology 20110701

• Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.

  AIDS research and human retroviruses 20110701

• Changes in cerebral function parameters in HIV type 1-infected subjects switching to darunavir/ritonavir either as monotherapy or with nucleoside analogues.

  AIDS research and human retroviruses 20110701

• Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.

  Journal of clinical pharmacology 20110701

• Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

  British journal of clinical pharmacology 20110701

• Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.

  The American journal of drug and alcohol abuse 20110701

• [Simplification to lopinavir/ritonavir monotherapy in HIV-infected children].

  Anales de pediatria (Barcelona, Spain : 2003) 20110701

• Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• Species independence in brain tissue binding using brain homogenates.

  Drug metabolism and disposition: the biological fate of chemicals 20110701

• Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

  European journal of obstetrics, gynecology, and reproductive biology 20110701

• Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

  Journal of acquired immune deficiency syndromes (1999) 20110701

• Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.

  The Journal of antimicrobial chemotherapy 20110701

• In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.

  The Journal of pharmacology and experimental therapeutics 20110701

• Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).

  HIV medicine 20110701

• Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices.

  Applied health economics and health policy 20110701

• Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

  AIDS patient care and STDs 20110701

• Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.

  The new microbiologica 20110701

• Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

  AIDS (London, England) 20110619

• Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops.

  AIDS (London, England) 20110619

• Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

  The Journal of infectious diseases 20110615

• Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.

  AIDS research and human retroviruses 20110601

• Tetherin and its viral antagonists.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110601

• Surface-active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug load.

  Journal of pharmaceutical sciences 20110601

• A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

  Journal of pharmaceutical sciences 20110601

• Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.

  Therapeutic drug monitoring 20110601

• Cushing's syndrome due to antiretroviral-budesonide interaction.

  The Annals of pharmacotherapy 20110601

• Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

  British journal of clinical pharmacology 20110601

• Management of HIV infection in treatment-naive patients: a review of the most current recommendations.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110601

• Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.

  AIDS patient care and STDs 20110601

• Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.

  Current HIV research 20110601

• Darunavir: an effective protease inhibitor for HIV-infected patients.

  Expert review of anti-infective therapy 20110601

• [Exogenous Cushing's syndrome as a serious side-effect of therapy with ritonavir an inhaled fluticasone].

  Klinicka mikrobiologie a infekcni lekarstvi 20110601

• Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

  Life sciences 20110523

• Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization.

  Journal of pharmaceutical and biomedical analysis 20110515

• Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).

  Heart (British Cardiac Society) 20110515

• High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20110515

• Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110501

• Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.

  AIDS research and human retroviruses 20110501

• Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20110501

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• Prospective one-year bone loss in treatment-naïve HIV+ men and women on single or multiple drug HIV therapies.

  Bone 20110501

• HIV-1 integrase inhibitor resistance and its clinical implications.

  The Journal of infectious diseases 20110501

• Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.

  Bioanalysis 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx.

  Internal medicine journal 20110501

• Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.

  AIDS (London, England) 20110424

• Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.

  AIDS (London, England) 20110424

• Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20110415

• Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

  Annals of internal medicine 20110405

• Excipient-mediated supersaturation stabilization in human intestinal fluids.

  Molecular pharmaceutics 20110404

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas.

  Journal of neuro-oncology 20110401

• Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.

  Scandinavian journal of infectious diseases 20110401

• Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

  Journal of acquired immune deficiency syndromes (1999) 20110401

• The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110401

• Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.

  The Journal of infection 20110401

• [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].

  Enfermedades infecciosas y microbiologia clinica 20110401

• Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.

  Expert opinion on drug metabolism & toxicology 20110401

• Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.

  Clinical pharmacokinetics 20110401

• Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

  Clinical pharmacokinetics 20110401

• Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.

  British journal of clinical pharmacology 20110401

• Nanomedicine for oral chemotherapy.

  Nanomedicine (London, England) 20110401

• First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data.

  Prescrire international 20110401

• Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.

  Journal of pharmacy practice 20110401

• Clinical management of HIV drug resistance.

  Viruses 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.

  AIDS (London, England) 20110313

• Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.

  Journal of controlled release : official journal of the Controlled Release Society 20110310

• Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.

  Journal of clinical pharmacology 20110301

• The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

  HIV medicine 20110301

• Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.

  HIV medicine 20110301

• Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.

  HIV medicine 20110301

• Interaction involving tadalafil and CYP3A4 inhibition by ritonavir.

  Scandinavian journal of infectious diseases 20110301

• Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.

  European journal of clinical pharmacology 20110301

• Retinal pigment epitheliopathy, macular telangiectasis, and intraretinal crystal deposits in HIV-positive patients receiving ritonavir.

  Retina (Philadelphia, Pa.) 20110301

• Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

  Basic & clinical pharmacology & toxicology 20110301

• Microsphere preparation using the untoxic solvent glycofurol.

  Pharmaceutical research 20110301

• Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease.

  Intensive care medicine 20110301

• Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.

  Journal of acquired immune deficiency syndromes (1999) 20110301

• Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction.

  Pharmacological research 20110301

• Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

  The Journal of antimicrobial chemotherapy 20110301

• Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.

  The Lancet. Infectious diseases 20110301

• Characterization of HIV-1 from patients with virological failure to a boosted protease inhibitor regimen.

  Journal of medical virology 20110301

• [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

  Enfermedades infecciosas y microbiologia clinica 20110301

• Therapy. Direct purchasers may proceed with claims against Abbott.

  AIDS policy & law 20110301

• First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

  AIDS (London, England) 20110220

• Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

  AIDS (London, England) 20110220

• Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.

  Journal of clinical pharmacology 20110201

• The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

  Journal of clinical pharmacology 20110201

• [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].

  Medecine et maladies infectieuses 20110201

• Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

  European journal of clinical pharmacology 20110201

• A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

  Journal of lipid research 20110201

• Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

  The Journal of antimicrobial chemotherapy 20110201

• Protease inhibitor monotherapy.

  Current opinion in infectious diseases 20110201

• High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110201

• Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110201

• 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

  British journal of clinical pharmacology 20110201

• Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.

  Therapeutic drug monitoring 20110201

• Poor differential adherence of ritonavir tablets used as protease inhibitor booster.

  AIDS patient care and STDs 20110201

• Ritonavir-induced acute kidney injury: kidney biopsy findings and review of literature.

  Clinical nephrology 20110201

• Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

  Pharmacotherapy 20110201

• Pharmacoeconomics of darunavir.

  Expert review of pharmacoeconomics & outcomes research 20110201

• From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients.

  Journal of clinical medicine research 20110201

• Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.

  AIDS (London, England) 20110128

• Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial.

  AIDS (London, England) 20110128

• Darunavir/ritonavir monotherapy in clinical practice.

  AIDS (London, England) 20110102

• Regulation of circulating sclerostin levels by sex steroids in women and in men.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110101

• Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater.

  Water research 20110101

• Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.

  Contemporary clinical trials 20110101

• Identification of clinically used drugs that activate pregnane X receptors.

  Drug metabolism and disposition: the biological fate of chemicals 20110101

• Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.

  Expert opinion on pharmacotherapy 20110101

• Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.

  Current HIV research 20110101

• Long-term safety from the raltegravir clinical development program.

  Current HIV research 20110101

• Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats.

  Biological & pharmaceutical bulletin 20110101

• Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.

  Current HIV research 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.

  AIDS research and therapy 20110101

• Taking multiple infections of cells and recombination into account leads to small within-host effective-population-size estimates of HIV-1.

  PloS one 20110101

• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

  BMC infectious diseases 20110101

• Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• Interplay between HIV entry and transportin-SR2 dependency.

  Retrovirology 20110101

• Clinical significance of HIV-1 coreceptor usage.

  Journal of translational medicine 20110101

• Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

  Journal of medical economics 20110101

• Human immunodeficiency virus type 2 in two Saudi families.

  Annals of Saudi medicine 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.

  Antiviral therapy 20110101

• Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

  Antiviral therapy 20110101

• Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.

  Antiviral therapy 20110101

• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  AIDS research and therapy 20110101

• Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs.

  BMC infectious diseases 20110101

• Antiretroviral therapy-associated acute motor and sensory axonal neuropathy.

  Case reports in neurology 20110101

• Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.

  Journal of medical case reports 20110101

• Penicillium marneffei Infection in AIDS.

  Pathology research international 20110101

• HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.

  Lipids in health and disease 20110101

• Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.

  PloS one 20110101

• Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.

  PloS one 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Timely HAART initiation may pave the way for a better viral control.

  BMC infectious diseases 20110101

• Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

  PloS one 20110101

• Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.

  PloS one 20110101

• A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial.

  Trials 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Sex differences in drug disposition.

  Journal of biomedicine & biotechnology 20110101

• Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease.

  Retrovirology 20110101

• Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series.

  Radiation oncology (London, England) 20110101

• [Renal adverse reactions of antiretroviral medication: proximal tubular dysfunction associated with tenofovir].

  Nederlands tijdschrift voor geneeskunde 20110101

• Highly active antiretroviral therapy: Does it Sound toxic?

  Journal of pharmacy & bioallied sciences 20110101

• Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.

  The Indian journal of tuberculosis 20110101

• The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.

  Antiviral therapy 20110101

• Interaction between antiretroviral drugs and acenocoumarol.

  Antiviral therapy 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs.

  PloS one 20110101

• Comparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patients.

  Cardiovascular ultrasound 20110101

• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

  European journal of medical research 20110101

• Saquinavir: prolongation of PR and QT intervals.

  Prescrire international 20110101

• Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.

  Internal medicine (Tokyo, Japan) 20110101

• Chronic action of association of zidovudine, lamivudine and ritonavir on pregnant rats. A biologic assay.

  Clinical and experimental obstetrics & gynecology 20110101

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

  European journal of medical research 20110101

• Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.

  European journal of medical research 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia.

  AIDS research and treatment 20110101

• Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries.

  AIDS research and treatment 20110101

• Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

  Breast cancer : basic and clinical research 20110101

• Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

  PloS one 20110101

• Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

  Antiviral therapy 20110101

• Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.

  Antiviral therapy 20110101

• Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.

  Antiviral therapy 20110101

• Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.

  AIDS research and therapy 20110101

• Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.

  Malaria journal 20110101

• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

  The open medicinal chemistry journal 20110101

• Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.

  Cardiology research and practice 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial.

  The open AIDS journal 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

  Molecular brain 20110101

• Breast Cancer in the Setting of HIV.

  Pathology research international 20110101

• Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

  PloS one 20110101

• Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.

  HIV clinical trials 20110101

• Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

  Antiviral therapy 20110101

• Update on the optimal use of voriconazole for invasive fungal infections.

  Infection and drug resistance 20110101

• Tolvaptan, hyponatremia, and heart failure.

  International journal of nephrology and renovascular disease 20110101

• Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.

  European journal of medical research 20110101

• Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand.

  BMC public health 20110101

• An Apple-core Lesion in the Colon: An Infectious Etiology.

  Journal of global infectious diseases 20110101

• Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

  Molecular cancer 20110101

• Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.

  PloS one 20110101

• Atazanavir in children.

  Prescrire international 20110101

• SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques.

  Retrovirology 20110101

• Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

  PloS one 20110101

• Does HAART efficacy translate to effectiveness? Evidence for a trial effect.

  PloS one 20110101

• Recurrent Meningitis and Subarachnoid Hemorrhage Due to Salmonella in an HIV+ Patient: Case Report and Mini-Review of the Literature.

  The open AIDS journal 20110101

• Clinical therapeutics in pregnancy.

  Journal of biomedicine & biotechnology 20110101

• Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

  BMC pediatrics 20110101

• Effects of the association zidovudine plus ritonavir on the liver and kidneys of pregnant rats. Morphological and biochemical aspects.

  Clinical and experimental obstetrics & gynecology 20110101

• An overview of post exposure prophylaxis for HIV in health care personals: Gujarat scenario.

  Indian journal of sexually transmitted diseases and AIDS 20110101

• Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

  PloS one 20110101

• Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

  PloS one 20110101

• New hepatitis C therapies in clinical development.

  European journal of medical research 20110101

• Long-term outcomes of liver transplant patients with human immunodeficiency virus infection and end-stage-liver-disease: single center experience.

  European journal of medical research 20110101

• The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.

  Antiviral therapy 20110101

• [Evidence-based therapeutic drug monitoring for indinavir].

  Therapie 20110101

• Antithrombotic medication for cardioembolic stroke prevention.

  Stroke research and treatment 20110101

• Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa.

  PloS one 20110101

• Pregnancy and virologic response to antiretroviral therapy in South Africa.

  PloS one 20110101

• Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy.

  BMC complementary and alternative medicine 20110101

• Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study.

  Journal of the International AIDS Society 20110101

• Kaposi sarcoma of the adrenal gland resembling epithelioid angiosarcoma: a case report.

  Sarcoma 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Nephrotoxicity of HAART.

  AIDS research and treatment 20110101

• HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

  Retrovirology 20110101

• Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy.

  Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20110101

• HIV-Associated Venous Thromboembolism.

  Mediterranean journal of hematology and infectious diseases 20110101

• Natural antioxidant dihydroxybenzyl alcohol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human endothelial cells.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Upper limb artery segmental occlusions due to chronic use of ergotamine combined with itraconazole, treated by thrombolysis.

  Thrombosis journal 20110101

• HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.

  PloS one 20110101

• Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

  PloS one 20110101

• HIV, Hepatitis B, and Hepatitis C in Zambia.

  Journal of global infectious diseases 20110101

• Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.

  PloS one 20110101

• Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.

  BMC public health 20110101

• Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.

  PloS one 20110101

• A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

  PloS one 20110101

• Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism.

  BMC medical genetics 20110101

• Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

  PloS one 20110101

• Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects.

  Arzneimittel-Forschung 20110101

• Primary cutaneous B-cell lymphoma successfully treated with highly active antiretroviral therapy alone: a case report and review of the literature.

  Indian journal of dermatology 20110101

• Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system.

  Journal of pharmacy & bioallied sciences 20110101

• HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4.

  PloS one 20110101

• Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients.

  AIDS reviews 20110101

• Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.

  Drug metabolism and drug interactions 20110101

• Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions.

  Retrovirology 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines.

  BMC cancer 20110101

• Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.

  PloS one 20110101

• Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department.

  PloS one 20110101

• Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil.

  PloS one 20110101

• Resistance data in the ARTEN trial.

  Antiviral therapy 20110101

• Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

  Journal of pharmacology & pharmacotherapeutics 20110101

• Human immunodeficiency virus and the endocrine system.

  Indian journal of endocrinology and metabolism 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Human immunodeficiency virus endocrinopathy.

  Indian journal of endocrinology and metabolism 20110101

• Choosing a gliptin.

  Indian journal of endocrinology and metabolism 20110101

• Nordihydroguaiaretic acid (NDGA) inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART.

  PloS one 20110101

• In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.

  International journal of nanomedicine 20110101

• CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

  BMJ (Clinical research ed.) 20110101

• Drugs for malaria: something old, something new, something borrowed.

  F1000 biology reports 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Undernutrition among HIV-positive children in Dar es Salaam, Tanzania: antiretroviral therapy alone is not enough.

  BMC public health 20110101

• Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.

  PloS one 20110101

• AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

  BMC research notes 20110101

• Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease in a Patient with HIV Infection: Dual Clinical Benefit.

  Case reports in neurology 20110101

• Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs.

  PloS one 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis.

  Cardiovascular diabetology 20110101

• Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy.

  PloS one 20110101

• Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

  ClinicoEconomics and outcomes research : CEOR 20110101

• Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.

  BMC infectious diseases 20110101

• Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan.

  Journal of advanced pharmaceutical technology & research 20110101

• A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

  BMC bioinformatics 20110101

• Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

  PloS one 20110101

• Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study.

  BMC pulmonary medicine 20110101

• Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

  HIV clinical trials 20110101

• Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil.

  Revista do Instituto de Medicina Tropical de Sao Paulo 20110101

• Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96.

  HIV clinical trials 20110101

• Nanomedicine as an emerging approach against intracellular pathogens.

  International journal of nanomedicine 20110101

• A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Critical appraisal of ticagrelor in the management of acute coronary syndrome.

  Therapeutics and clinical risk management 20110101

• Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

  Patient preference and adherence 20110101

• Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

  International journal of nanomedicine 20110101

• Osteopenia and osteoporosis in people living with HIV: multiprofessional approach.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Lipodystrophy in HIV patients: its challenges and management approaches.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Pharmacogenomics: what is next?

  Frontiers in pharmacology 20110101

• Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.

  Clinical pharmacology : advances and applications 20110101

• Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.

  Chemotherapy research and practice 20110101

• Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

  Malaria research and treatment 20110101

• High FDG uptake on FDG-PET scan in HIV-1 infected patient with advanced disease.

  Acta clinica Belgica 20110101

• [Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20110101

• Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

  Acta naturae 20110101

• Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma.

  Indian journal of pharmaceutical sciences 20110101

• Micellar electrokinetic chromatography method development for determination of impurities in ritonavir.

  Journal of pharmaceutical and biomedical analysis 20101215

• Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20101201

• LC-MS/MS studies of ritonavir and its forced degradation products.

  Journal of pharmaceutical and biomedical analysis 20101201

• Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.

  Drug metabolism letters 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

  Journal of acquired immune deficiency syndromes (1999) 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin.

  Arteriosclerosis, thrombosis, and vascular biology 20101201

• Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.

  Antiviral research 20101201

• Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

  Journal of medical virology 20101201

• Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.

  The Journal of pharmacy and pharmacology 20101201

• Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition.

  Journal of internal medicine 20101201

• Does lopinavir/ritonavir alter the primary gingival epithelium?

  Expert review of anti-infective therapy 20101201

• Avascular necrosis of the talus in a HIV-infected patient.

  Foot & ankle international 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.

  The Indian journal of medical research 20101201

• Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.

  AIDS (London, England) 20101127

• Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.

  The Journal of biological chemistry 20101119

• A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

  The Journal of infectious diseases 20101115

• Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.

  AIDS (London, England) 20101113

• The cancer-HIV/AIDS treatment conundrum.

  Journal of the National Cancer Institute 20101103

• In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.

  Journal of pharmaceutical and biomedical analysis 20101102

• HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.

  Mycoses 20101101

• Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.

  HIV medicine 20101101

• Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20101101

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

  The Journal of antimicrobial chemotherapy 20101101

• Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.

  AIDS research and human retroviruses 20101101

• Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.

  AIDS research and human retroviruses 20101101

• Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

  Clinical pharmacology and therapeutics 20101101

• Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20101101

• Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.

  Advances in therapy 20101101

• Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.

  Hepatology (Baltimore, Md.) 20101101

• Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

  Circulation 20101101

• Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.

  The Annals of pharmacotherapy 20101101

• The Mycobacterium tuberculosis drugome and its polypharmacological implications.

  PLoS computational biology 20101101

• A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).

  AIDS research and human retroviruses 20101101

• HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.

  Biopharmaceutics & drug disposition 20101101

• [Morphological and physiological analysis of livers and kidneys of pregnant rats and their fetuses treated by the association of zidovudine, lamivudine and ritonavir for the whole period of pregnancy].

  Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 20101101

• First-line raltegravir. No evidence of comparative effectiveness.

  Prescrire international 20101101

• Molecular Basis for Drug Resistance in HIV-1 Protease.

  Viruses 20101101

• Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.

  Proceedings of the National Academy of Sciences of the United States of America 20101026

• Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.

  AIDS (London, England) 20101023

• Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies.

  Statistics in medicine 20101015

• Antiretroviral therapies in women after single-dose nevirapine exposure.

  The New England journal of medicine 20101014

• Antiretroviral treatment for children with peripartum nevirapine exposure.

  The New England journal of medicine 20101014

• Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.

  Journal of molecular modeling 20101001

• Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.

  HIV medicine 20101001

• Dose-related reduction in bupropion plasma concentrations by ritonavir.

  Journal of clinical pharmacology 20101001

• Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

  European journal of clinical pharmacology 20101001

• Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.

  Diabetes care 20101001

• Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers.

  The Journal of antimicrobial chemotherapy 20101001

• Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

  European journal of clinical pharmacology 20101001

• Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

  The Journal of antimicrobial chemotherapy 20101001

• Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity.

  Journal of neurochemistry 20101001

• Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

  The Journal of antimicrobial chemotherapy 20101001

• Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

  Drugs 20101001

• Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

  Journal of Korean medical science 20101001

• Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines.

  Current HIV research 20101001

• Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.

  AIDS (London, England) 20100924

• Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.

  AIDS (London, England) 20100924

• Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

  AIDS (London, England) 20100924

• Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

  AIDS (London, England) 20100924

• Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy.

  AIDS (London, England) 20100924

• Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

  Annals of internal medicine 20100921

• Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

  AIDS (London, England) 20100910

• Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.

  Drugs 20100910

• HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

  Journal of pharmaceutical and biomedical analysis 20100905

• The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.

  Journal of clinical pharmacology 20100901

• No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.

  HIV medicine 20100901

• pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.

  The Journal of pharmacology and experimental therapeutics 20100901

• In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.

  The Journal of antimicrobial chemotherapy 20100901

• Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.

  Urology 20100901

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients.

  Current HIV research 20100901

• Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient.

  The Journal of asthma : official journal of the Association for the Care of Asthma 20100901

• KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy.

  Emerging infectious diseases 20100901

• [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].

  Medecine et maladies infectieuses 20100901

• New treatments for chronic hepatitis C.

  The Korean journal of hepatology 20100901

• [Metabolism of 3-cyanomethyl-4-methyl-DCK, a new anti-HIV candidate, in human intestinal microsomes].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100901

• Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

  AIDS (London, England) 20100824

• Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.

  The Pediatric infectious disease journal 20100801

• Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20100801

• Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

  The Journal of pharmacology and experimental therapeutics 20100801

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  The Journal of antimicrobial chemotherapy 20100801

• Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.

  Pharmacotherapy 20100801

• Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

  International journal of clinical practice 20100801

• Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.

  AIDS research and human retroviruses 20100801

• Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.

  Current opinion in investigational drugs (London, England : 2000) 20100801

• Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel.

  Viruses 20100801

• Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

  Toxins 20100801

• Neither ritonavir nor darunavir affect cell surface expression of tetherin or Vpu-mediated tetherin down-modulation.

  AIDS (London, England) 20100731

• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  Archives of internal medicine 20100726

• Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

  AIDS (London, England) 20100717

• Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults.

  AIDS (London, England) 20100717

• [Cushing syndrome after steroid-infiltration in two HIV-patients with antiretroviral therapy].

  Praxis 20100707

• Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.

  Genomics 20100701

• Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

  Antimicrobial agents and chemotherapy 20100701

• Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

  The Journal of antimicrobial chemotherapy 20100701

• Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats.

  Veterinary journal (London, England : 1997) 20100701

• Drug interactions during periodontal therapy in HIV-infected subjects.

  Mini reviews in medicinal chemistry 20100701

• Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

  British journal of pharmacology 20100701

• Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate.

  International journal of impotence research 20100701

• Resistance to integrase inhibitors.

  Viruses 20100701

• Role of Gag in HIV Resistance to Protease Inhibitors.

  Viruses 20100701

• Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation.

  AIDS (London, England) 20100619

• Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.

  Molecular pharmaceutics 20100607

• Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen.

  Irish journal of medical science 20100601

• Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.

  Journal of pharmaceutical sciences 20100601

• Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.

  Atherosclerosis 20100601

• Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.

  Journal of acquired immune deficiency syndromes (1999) 20100601

• A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

  Clinical pharmacology and therapeutics 20100601

• Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients.

  The Pediatric infectious disease journal 20100601

• Antiretroviral therapy and bone mineral measurements in HIV-infected youths.

  Bone 20100601

• Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir.

  AAPS PharmSciTech 20100601

• Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.

  Expert opinion on pharmacotherapy 20100601

• Adrenal function in HIV infection.

  Current opinion in endocrinology, diabetes, and obesity 20100601

• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.

  AIDS care 20100601

• Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.

  Clinical pharmacokinetics 20100601

• Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.

  Archives of disease in childhood 20100601

• Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

  PLoS pathogens 20100601

• Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction.

  International journal of emergency medicine 20100601

• Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.

  Canadian journal of physiology and pharmacology 20100601

• Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

  AIDS (London, England) 20100515

• Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy.

  AIDS (London, England) 20100515

• Mass spectrometry and renal calculi.

  Journal of medicine and life 20100515

• Adrenal suppression and Cushing's syndrome secondary to ritonavir and budesonide.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20100504

• Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.

  Medical mycology 20100501

• Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

  HIV medicine 20100501

• Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20100501

• HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

  Biochimica et biophysica acta 20100501

• Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation.

  Antiviral research 20100501

• Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

  The Journal of antimicrobial chemotherapy 20100501

• Long-term ritonavir exposure increases fatty acid and glycerol recycling in 3T3-L1 adipocytes as compensatory mechanisms for increased triacylglycerol hydrolysis.

  Endocrinology 20100501

• Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

  The Journal of antimicrobial chemotherapy 20100501

• Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

  Journal of virology 20100501

• Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.

  The Journal of antimicrobial chemotherapy 20100501

• Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.

  Clinical pharmacokinetics 20100501

• Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.

  AIDS research and human retroviruses 20100501

• Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

  British journal of clinical pharmacology 20100501

• Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

  British journal of clinical pharmacology 20100501

• Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.

  AIDS (London, England) 20100424

• Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100416

• Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

  The Journal of infectious diseases 20100415

• Antiretroviral therapy in children with tuberculosis: progress toward defining the issues.

  The Journal of infectious diseases 20100415

• Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids.

  Molecular pharmaceutics 20100405

• High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

  European journal of clinical pharmacology 20100401

• Lopinavir protein binding in HIV-1-infected pregnant women.

  HIV medicine 20100401

• Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting.

  European journal of clinical pharmacology 20100401

• Lipocalin-2 deficiency attenuates insulin resistance associated with aging and obesity.

  Diabetes 20100401

• Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

  The Journal of antimicrobial chemotherapy 20100401

• Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).

  Journal of clinical pharmacology 20100401

• In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.

  Cancer chemotherapy and pharmacology 20100401

• Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

  Pharmacogenetics and genomics 20100401

• Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100401

• Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.

  The Journal of infectious diseases 20100401

• Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.

  Archives of toxicology 20100401

• The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

  Therapeutic drug monitoring 20100401

• Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.

  Paediatric drugs 20100401

• Chronic thromboembolic pulmonary hypertension.

  Current treatment options in cardiovascular medicine 20100401

• Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.

  AIDS research and human retroviruses 20100401

• Arrhythmia risk with saquinavir.

  AIDS patient care and STDs 20100401

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20100401

• FDA notifications. Potential serious effect of combination saquinavir-ritonavir.

  AIDS alert 20100401

• Antiviral therapy for hepatitis C virus: beyond the standard of care.

  Viruses 20100401

• Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.

  AIDS (London, England) 20100327

• Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

  The Journal of infectious diseases 20100315

• Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

  Archives of internal medicine 20100308

• Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.

  HIV medicine 20100301

• Simultaneous determination of levetiracetam and its acid metabolite (ucb L057) in serum/plasma by liquid chromatography tandem mass spectrometry.

  Clinical biochemistry 20100301

• Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

  Journal of acquired immune deficiency syndromes (1999) 20100301

• Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

  Clinical pharmacology and therapeutics 20100301

• Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.

  The Journal of antimicrobial chemotherapy 20100301

• HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

  International journal of STD & AIDS 20100301

• Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100301

• Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

  Xenobiotica; the fate of foreign compounds in biological systems 20100301

• Abstracts of the 16th Annual Society on NeuroImmune Pharmacology (SNIP) Conference. April 13-17, 2010. Manhattan Beach, California, USA.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100301

• Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.

  International journal of clinical pharmacology and therapeutics 20100301

• Single-tablet Quad regimen achieves high rate of virologic suppression.

  AIDS patient care and STDs 20100301

• Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

  British journal of clinical pharmacology 20100301

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Disappointing results for vicriviroc.

  AIDS patient care and STDs 20100301

• Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

  PLoS neglected tropical diseases 20100301

• Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

  The Journal of infectious diseases 20100215

• Xenotropic murine leukemia virus-related virus is susceptible to AZT.

  Virology 20100205

• Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.

  Journal of pharmaceutical sciences 20100201

• HIV infection of the male genital tract--consequences for sexual transmission and reproduction.

  International journal of andrology 20100201

• Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

  HIV medicine 20100201

• Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).

  Journal of pharmaceutical sciences 20100201

• [Mechanisms of pharmacokinetic drug-drug interactions].

  La Revue de medecine interne 20100201

• Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.

  Journal of pharmaceutical sciences 20100201

• Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.

  Journal of acquired immune deficiency syndromes (1999) 20100201

• Inulin solid dispersion technology to improve the absorption of the BCS Class IV drug TMC240.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100201

• Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.

  Clinical pharmacology and therapeutics 20100201

• Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).

  Antiviral research 20100201

• Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.

  Therapeutic drug monitoring 20100201

• HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

  Pharmacogenetics and genomics 20100201

• Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.

  International journal of STD & AIDS 20100201

• GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20100201

• [LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• HIV Genetic Diversity and Drug Resistance.

  Viruses 20100201

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

  Lancet (London, England) 20100130

• HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

  Journal of medicinal chemistry 20100128

• The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.

  AIDS (London, England) 20100116

• The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

  AIDS (London, England) 20100116

• Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.

  AIDS (London, England) 20100102

• Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.

  HIV medicine 20100101

• HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

  Gastroenterology 20100101

• Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

  Antiviral research 20100101

• Factors influencing lopinavir and atazanavir plasma concentration.

  The Journal of antimicrobial chemotherapy 20100101

• Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

  International journal of clinical practice 20100101

• Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial.

  The Journal of antimicrobial chemotherapy 20100101

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism.

  European journal of clinical pharmacology 20100101

• [Interactions with antiretroviral drugs].

  Der Internist 20100101

• The cost and incidence of prescribing errors among privately insured HIV patients.

  PharmacoEconomics 20100101

• The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

  British journal of pharmacology 20100101

• 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.

  British journal of clinical pharmacology 20100101

• Severe toxicity related to a pharmacokinetic interaction between docetaxel and ritonavir in HIV-infected patients.

  British journal of clinical pharmacology 20100101

• Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.

  BMC gastroenterology 20100101

• The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.

  PloS one 20100101

• The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site.

  Retrovirology 20100101

• Towards a Patent Pool for HIV Medicines: The Background.

  The open AIDS journal 20100101

• Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

  The open AIDS journal 20100101

• Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.

  PloS one 20100101

• Pooling ARV Drug Patents: A Pro-Access Fitting Strategy?

  The open AIDS journal 20100101

• Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.

  Antiviral therapy 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

  PloS one 20100101

• Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells.

  Molecular cancer 20100101

• Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.

  Intervirology 20100101

• Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics.

  The open AIDS journal 20100101

• Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes.

  Drug metabolism letters 20100101

• Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose.

  Drug metabolism letters 20100101

• Technology Development Through Pooling ARV Drug Patents: A Vision from China.

  The open AIDS journal 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Abacavir/lamivudine combination in the treatment of HIV: a review.

  Therapeutics and clinical risk management 20100101

• Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

  AIDS research and therapy 20100101

• Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

  Antiviral therapy 20100101

• The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

  Antiviral therapy 20100101

• Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.

  Antiviral therapy 20100101

• The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs.

  Antiviral therapy 20100101

• Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.

  Antiviral therapy 20100101

• Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

  HIV clinical trials 20100101

• Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

  PloS one 20100101

• The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.

  PloS one 20100101

• A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study.

  Analytical chemistry insights 20100101

• HAART and the liver: friend or foe?

  European journal of medical research 20100101

• Semen may harbor HIV despite effective HAART: another piece in the puzzle.

  PloS one 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• HIV protease inhibitors activate the adipocyte renin angiotensin system.

  Antiviral therapy 20100101

• 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences.

  Journal of the International AIDS Society 20100101

• An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.

  PloS one 20100101

• Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV clinical trials 20100101

• Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.

  PloS one 20100101

• A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008.

  PloS one 20100101

• Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?

  European journal of medical research 20100101

• Co-lethality studied as an asset against viral drug escape: the HIV protease case.

  Biology direct 20100101

• Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

  AIDS research and therapy 20100101

• HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.

  Antiviral therapy 20100101

• Pulmonary Embolism Mimicking Pneumonia in a HIV Patient.

  Case reports in medicine 20100101

• The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.

  Drug metabolism and pharmacokinetics 20100101

• Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

  PloS one 20100101

• Use of statin therapy to reduce cardiovascular risk in older patients.

  Current gerontology and geriatrics research 20100101

• Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

  PloS one 20100101

• Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces.

  BMC health services research 20100101

• [Meta-analysis of the effectiveness of the strategy of monotherapy with boosted protease inhibitors in HIV+ patients].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101

• High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.

  Biological & pharmaceutical bulletin 20100101

• Diagnosis of systemic toxoplasmosis with HIV infection using DNA extracted from paraffin-embedded tissue for polymerase chain reaction: a case report.

  Journal of medical case reports 20100101

• Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

  BMC gastroenterology 20100101

• Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.

  Antiviral therapy 20100101

• Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients.

  AIDS research and therapy 20100101

• Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.

  HIV clinical trials 20100101

• Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.

  HIV clinical trials 20100101

• Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.

  HIV clinical trials 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Acute adrenal crisis in an asthmatic child treated with inhaled fluticasone proprionate.

  International journal of pediatric endocrinology 20100101

• Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

  AIDS reviews 20100101

• Assessing the performance of a computer-based policy model of HIV and AIDS.

  PloS one 20100101

• Anti-retroviral therapy-induced status epilepticus in 'pseudo-HIV serodeconversion'.

  General hospital psychiatry 20100101

• Getting the balance right: Established and emerging therapies for major depressive disorders.

  Neuropsychiatric disease and treatment 20100101

• Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk.

  PloS one 20100101

• Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.

  Vascular health and risk management 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.

  Retrovirology 20100101

• Aging, human immunodeficiency virus, and bone health.

  Clinical interventions in aging 20100101

• Lymphoma in HIV patients: Varied presentations.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes.

  Scientia pharmaceutica 20100101

• Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia.

  PloS one 20100101

• The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.

  PloS one 20100101

• Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort.

  PloS one 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

  European journal of medical research 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

  HIV clinical trials 20100101

• Routine HIV screening in France: clinical impact and cost-effectiveness.

  PloS one 20100101

• Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

  Antiviral therapy 20100101

• Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.

  Antiviral therapy 20100101

• Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.

  Antiviral therapy 20100101

• Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.

  Antiviral therapy 20100101

• Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

  Antiviral therapy 20100101

• Drug interaction and pharmacist.

  Journal of young pharmacists : JYP 20100101

• Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20100101

• The initial step in human immunodeficiency virus type 1 GagProPol processing can be regulated by reversible oxidation.

  PloS one 20100101

• Rapidly growing nodule on the finger of a pregnant woman.

  Annals of Saudi medicine 20100101

• Models of RNA virus evolution and their roles in vaccine design.

  Immunome research 20100101

• Emergency contraception: potential role of ulipristal acetate.

  International journal of women's health 20100101

• Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen.

  AIDS research and therapy 20100101

• Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction.

  General hospital psychiatry 20100101

• Silodosin in the treatment of benign prostatic hyperplasia.

  Drug design, development and therapy 20100101

• Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

  Drug design, development and therapy 20100101

• Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.

  HIV clinical trials 20100101

• Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.

  Antiviral therapy 20100101

• Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

  Antiviral therapy 20100101

• Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution.

  AIDS research and therapy 20100101

• Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.

  Journal of visualized experiments : JoVE 20100101

• Orphan drug: Development trends and strategies.

  Journal of pharmacy & bioallied sciences 20100101

• A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

  PharmacoEconomics 20100101

• Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

  PharmacoEconomics 20100101

• US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

  PharmacoEconomics 20100101

• Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

  PharmacoEconomics 20100101

• Pseudogout Associated Hip Pain in a Patient with HIV Infection.

  Case reports in medicine 20100101

• A critical look at the national essential medicines list of India 2003.

  Journal of pharmacology & pharmacotherapeutics 20100101

• Current trends in the treatment of asthma: focus on the simultaneous administration of salmeterol/fluticasone.

  Journal of asthma and allergy 20100101

• Saxagliptin for type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients.

  AIDS research and treatment 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus.

  Case reports in dermatology 20100101

• Tuberculosis of spine.

  Journal of craniovertebral junction & spine 20100101

• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

  Infection and drug resistance 20100101

• The use of anti-tuberculosis therapy for latent TB infection.

  Infection and drug resistance 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.

  Drug, healthcare and patient safety 20100101

• Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

  Indian journal of sexually transmitted diseases and AIDS 20100101

• Pharmacogenetics in the brazilian population.

  Frontiers in pharmacology 20100101

• Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

  HIV/AIDS (Auckland, N.Z.) 20100101

• HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• New and emerging agents in the management of lipodystrophy in HIV-infected patients.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Oral manifestations of HIV.

  Contemporary clinical dentistry 20100101

• Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor.

  Journal of blood medicine 20100101

• HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy.

  Movement disorders : official journal of the Movement Disorder Society 20091215

• [Raised tattoos in a human-immunodeficiency-virus-infected patient].

  Enfermedades infecciosas y microbiologia clinica 20091201

• Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

  Drug and alcohol dependence 20091201

• Endoplasmic reticulum stress-induced apoptosis in the development of diabetes: is there a role for adipose tissue and liver?

  Apoptosis : an international journal on programmed cell death 20091201

• Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.

  Pharmacy world & science : PWS 20091201

• Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir.

  Arteriosclerosis, thrombosis, and vascular biology 20091201

• Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells.

  Laboratory investigation; a journal of technical methods and pathology 20091201

• Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20091201

• Protease inhibitor resistance in South African children with virologic failure.

  The Pediatric infectious disease journal 20091201

• Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.

  The Pediatric infectious disease journal 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.

  The Annals of pharmacotherapy 20091201

• Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.

  The Annals of pharmacotherapy 20091201

• NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

  Nanomedicine (London, England) 20091201

• Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

  British journal of clinical pharmacology 20091201

• Antiretroviral therapy: new drugs, formulations, ideas, and strategies.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20091201

• HIV-1 Protease: Structural Perspectives on Drug Resistance.

  Viruses 20091201

• Current and Novel Inhibitors of HIV Protease.

  Viruses 20091201

• How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

  AIDS (London, England) 20091113

• EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.

  Toxicology letters 20091112

• Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

  HIV medicine 20091101

• Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

  The Journal of antimicrobial chemotherapy 20091101

• Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.

  The Journal of antimicrobial chemotherapy 20091101

• [Regimen simplification: lopinavir/ritonavir with or without efavirenz].

  Enfermedades infecciosas y microbiologia clinica 20091101

• Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

  The Journal of antimicrobial chemotherapy 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.

  Current HIV/AIDS reports 20091101

• Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients.

  Pharmacotherapy 20091101

• Clinical pharmacology, efficacy and safety of atazanavir: a review.

  Expert opinion on drug metabolism & toxicology 20091101

• PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.

  HIV medicine 20091101

• First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach.

  Current opinion in HIV and AIDS 20091101

• Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).

  Current opinion in HIV and AIDS 20091101

• A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

  Talanta 20091015

• Antiretroviral compounds and cholesterol efflux from macrophages.

  Atherosclerosis 20091001

• Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

  Experimental parasitology 20091001

• Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers.

  European journal of clinical pharmacology 20091001

• Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

  The Journal of antimicrobial chemotherapy 20091001

• Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20091001

• Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant.

  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20091001

• The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20091001

• A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.

  Journal of medical virology 20091001

• A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.

  HIV medicine 20091001

• Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20091001

• Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.

  Pharmacotherapy 20091001

• Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.

  Pharmacogenomics 20091001

• Ergotism caused by concurrent use of ritonavir and ergot alkaloids: a case report.

  Acta chirurgica Belgica 20091001

• Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid/liquid extraction, and ultrafast LC-MS/MS.

  Analytica chimica acta 20090928

• Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.

  AIDS (London, England) 20090924

• Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090915

• Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

  Bioorganic & medicinal chemistry letters 20090915

• Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

  AIDS (London, England) 20090910

• [Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal failure in a human immunodeficiency virus patient treated with ritonavir boosted atazanavir and fluticasone].

  Annales d'endocrinologie 20090901

• The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

  Basic & clinical pharmacology & toxicology 20090901

• Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

  The Journal of infectious diseases 20090901

• Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.

  Sexual health 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.

  Biological & pharmaceutical bulletin 20090901

• Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis.

  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20090901

• The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

  Expert review of anti-infective therapy 20090901

• [Cushing's syndrome induced by combined treatment with inhaled fluticasone and oral ritonavir].

  Revue des maladies respiratoires 20090901

• Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

  AIDS (London, England) 20090824

• Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

  Journal of acquired immune deficiency syndromes (1999) 20090815

• Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090815

• Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090801

• Lopinavir/ritonavir in pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin.

  Drug metabolism and disposition: the biological fate of chemicals 20090801

• Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

  Clinical pharmacology and therapeutics 20090801

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

  The Journal of antimicrobial chemotherapy 20090801

• Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.

  Pharmacotherapy 20090801

• Pharmacokinetic enhancers for HIV drugs.

  Current opinion in investigational drugs (London, England : 2000) 20090801

• Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient.

  Fundamental & clinical pharmacology 20090801

• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

  AIDS (London, England) 20090731

• First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

  AIDS (London, England) 20090717

• Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

  AIDS (London, England) 20090717

• In vitro anti-HIV activity of five selected South African medicinal plant extracts.

  Journal of ethnopharmacology 20090715

• Therapeutic drug monitoring of antiretrovirals for people with HIV.

  The Cochrane database of systematic reviews 20090708

• Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20090701

• Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

  Antimicrobial agents and chemotherapy 20090701

• Drug interactions between inhaled corticosteroids and enzymatic inhibitors.

  European journal of clinical pharmacology 20090701

• The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

  The Journal of antimicrobial chemotherapy 20090701

• Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

  Journal of clinical microbiology 20090701

• Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.

  European journal of clinical pharmacology 20090701

• Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.

  Addiction biology 20090701

• Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.

  Current HIV research 20090701

• Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

  British journal of clinical pharmacology 20090701

• Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090628

• Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

• Effectiveness of commercial inhibitors against subtype F HIV-1 protease.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.

  Infection 20090601

• Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane X receptor reporter gene, and Fa2N-4 and HepaRG cells.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

  The Journal of antimicrobial chemotherapy 20090601

• Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

  The Journal of antimicrobial chemotherapy 20090601

• Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.

  AIDS (London, England) 20090601

• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

  Journal of acquired immune deficiency syndromes (1999) 20090601

• Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus.

  Journal of medical virology 20090601

• Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

  AIDS (London, England) 20090601

• Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.

  AIDS (London, England) 20090601

• Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

  Infection 20090601

• Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir.

  Orthopedics 20090601

• Etravirine: new drug. Multidrug-resistant HIV: another option.

  Prescrire international 20090601

• Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.

  Prescrire international 20090601

• Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?

  Journal of infection in developing countries 20090601

• Atazanavir: a review of its use in the management of HIV-1 infection.

  Drugs 20090529

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090515

• Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

  Journal of medicinal chemistry 20090514

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.

  HIV medicine 20090501

• Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.

  The Journal of antimicrobial chemotherapy 20090501

• Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.

  Journal of pharmaceutical and biomedical analysis 20090501

• Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.

  American journal of physiology. Gastrointestinal and liver physiology 20090501

• Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090501

• First-line antiretroviral therapy in resource-limited settings: time to reconsider?

  The Journal of infectious diseases 20090501

• HSA binding of HIV protease inhibitors: a high-performance affinity chromatography study.

  Journal of separation science 20090501

• Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.

  Current drug safety 20090501

• Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy.

  Current HIV research 20090501

• FDA notifications. Generic lopinavir/ritonavir approved by FDA.

  AIDS alert 20090501

• Antiretroviral rounds. Happy 50th? Sedation for colonoscopy in HIV-infected patients.

  Journal watch. AIDS clinical care 20090501

• Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.

  Current oncology (Toronto, Ont.) 20090501

• Improvements in antiretroviral therapy outcomes over calendar time.

  Current opinion in HIV and AIDS 20090501

• Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem.

  Current cardiology reviews 20090501

• Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

  AIDS (London, England) 20090427

• Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.

  Journal of medicinal chemistry 20090423

• 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

  Journal of medicinal chemistry 20090423

• Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.

  Journal of chromatography. A 20090417

• A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

  Journal of acquired immune deficiency syndromes (1999) 20090415

• Salting-out assisted liquid/liquid extraction with acetonitrile: a new high throughput sample preparation technique for good laboratory practice bioanalysis using liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20090401

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.

  Clinical pharmacology and therapeutics 20090401

• Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression.

  Clinical pharmacology and therapeutics 20090401

• Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.

  Drug metabolism and disposition: the biological fate of chemicals 20090401

• Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.

  American journal of physiology. Endocrinology and metabolism 20090401

• Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

  Journal of acquired immune deficiency syndromes (1999) 20090401

• Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.

  AIDS research and human retroviruses 20090401

• Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

  AIDS research and human retroviruses 20090401

• FDA approves three generics.

  AIDS patient care and STDs 20090401

• Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

  Clinical therapeutics 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. Investigational pharmacologic boosters.

  Journal watch. AIDS clinical care 20090401

• Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.

  Drug metabolism letters 20090401

• Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

  AIDS (London, England) 20090327

• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.

  The Journal of infectious diseases 20090315

• Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

  Journal of neuroscience research 20090301

• GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

  Antimicrobial agents and chemotherapy 20090301

• Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

  The Journal of antimicrobial chemotherapy 20090301

• Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.

  The Journal of antimicrobial chemotherapy 20090301

• Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

  The Pediatric infectious disease journal 20090301

• Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.

  The American journal of pathology 20090301

• Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.

  Anesthesiology 20090301

• A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Transplacental passage of ritonavir-boosted darunavir in two pregnant women.

  International journal of STD & AIDS 20090301

• Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

  AIDS research and human retroviruses 20090301

• Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.

  PLoS pathogens 20090301

• Two newcomers may challenge ritonavir's position as the only booster for HIV therapy.

  Project Inform perspective 20090301

• Data demonstrate pharmacokinetic boosting activity of GS 9350.

  AIDS patient care and STDs 20090301

• Protease inhibitor levels in hair strongly predict virologic response to treatment.

  AIDS (London, England) 20090220

• Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.

  International journal of cancer 20090201

• Ritonavir and disulfiram have potential to inhibit caspase-1 mediated inflammation and reduce neurological sequelae after minor blast exposure.

  Medical hypotheses 20090201

• Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.

  Toxicology in vitro : an international journal published in association with BIBRA 20090201

• Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

  The Pediatric infectious disease journal 20090201

• Simultaneous liquid chromatographic analysis of ritonavir, quinine and 3-hydroxyquinine in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090201

• Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

  Journal of clinical pharmacology 20090201

• Warfarin-antiretroviral interactions.

  The Annals of pharmacotherapy 20090201

• Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20090201

• Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).

  HIV medicine 20090201

• ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.

  Pharmacogenomics 20090201

• Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.

  Advances in therapy 20090201

• Non-occupational postexposure prophylaxis for HIV: a systematic review.

  Health technology assessment (Winchester, England) 20090201

• [Atazanavir-induced nephrolithiasis].

  Enfermedades infecciosas y microbiologia clinica 20090201

• [Tipranavir: therapeutic drug monitoring in a pediatric patient with HIV infection].

  Enfermedades infecciosas y microbiologia clinica 20090201

• HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

  AIDS (London, England) 20090128

• Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.

  AIDS (London, England) 20090128

• A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.

  European journal of medical research 20090128

• Low atazanavir concentrations in cerebrospinal fluid.

  AIDS (London, England) 20090102

• Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.

  Clinical pharmacology and therapeutics 20090101

• Update on antiretroviral therapy.

  Archives of disease in childhood 20090101

• First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.

  The Journal of pharmacology and experimental therapeutics 20090101

• Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

  The Journal of antimicrobial chemotherapy 20090101

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

  The Journal of infectious diseases 20090101

• Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children.

  Pharmacology 20090101

• Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss.

  The American journal of pathology 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Anti-HIV drugs for cancer therapeutics: back to the future?

  The Lancet. Oncology 20090101

• Capsaicin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine pulmonary arteries.

  Medical science monitor : international medical journal of experimental and clinical research 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

  Clinical drug investigation 20090101

• The use of darunavir/ritonavir as intensification in low viremic HIV-infected patients treated with boosted protease inhibitor-containing regimens.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Survey of physician knowledge regarding antiretroviral medications in hospitalized HIV-infected patients.

  Journal of the International AIDS Society 20090101

• Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.

  Journal of biochemical and molecular toxicology 20090101

• Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.

  Enfermedades infecciosas y microbiologia clinica 20090101

• The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism.

  Nuclear receptor signaling 20090101

• Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles.

  Molecular pharmaceutics 20090101

• Comparison of Markov model and discrete-event simulation techniques for HIV.

  PharmacoEconomics 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.

  AIDS reviews 20090101

• Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.

  Antiviral therapy 20090101

• Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

  Antiviral therapy 20090101

• A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.

  Antiviral therapy 20090101

• Darunavir: a review of its use in the management of HIV infection in adults.

  Drugs 20090101

• HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

  PloS one 20090101

• Is PPARγ a prospective player in HIV-1-associated bone disease?

  PPAR research 20090101

• A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

  AIDS research and therapy 20090101

• Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.

  HIV clinical trials 20090101

• Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling.

  BMC public health 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.

  BMC medicine 20090101

• Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.

  Molecular cancer 20090101

• Ankle-brachial index in HIV infection.

  AIDS research and therapy 20090101

• Seven-year follow-up on lopinavir/ ritonavir monotherapy.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

  Antiviral therapy 20090101

• Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

  Antiviral therapy 20090101

• Life-threatening hemorrhage following subcutaneous heparin therapy.

  Therapeutics and clinical risk management 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

  PloS one 20090101

• Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.

  Antiviral therapy 20090101

• The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

  Antiviral therapy 20090101

• Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

  PloS one 20090101

• Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

  HIV clinical trials 20090101

• CROI round-up. New information on the heart, plus a possible alternative to Norvir and more.

  Positively aware : the monthly journal of the Test Positive Aware Network 20090101

• Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report.

  AIDS research and therapy 20090101

• Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection.

  Therapeutics and clinical risk management 20090101

• Bioequivalence study of two fixed dose combination tablet formulations of lopinavir and ritonavir in healthy volunteers.

  Arzneimittel-Forschung 20090101

• Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens.

  AIDS research and therapy 20090101

• Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.

  Clinical interventions in aging 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

  PloS one 20090101

• Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

  Antiviral therapy 20090101

• Reactivation from latency displays HIV particle budding at plasma membrane, accompanying CD44 upregulation and recruitment.

  Retrovirology 20090101

• Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.

  BMC infectious diseases 20090101

• Factors influencing quality of life of people living with HIV in Estonia: a cross-sectional survey.

  Journal of the International AIDS Society 20090101

• 9-Aminoacridine inhibition of HIV-1 Tat dependent transcription.

  Virology journal 20090101

• Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

  HIV clinical trials 20090101

• Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.

  HIV clinical trials 20090101

• Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).

  HIV clinical trials 20090101

• Novel methodology for antiretroviral quantitation in the female genital tract.

  HIV clinical trials 20090101

• Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.

  AIDS research and therapy 20090101

• The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.

  Interdisciplinary perspectives on infectious diseases 20090101

• Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

  Vascular health and risk management 20090101

• Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model.

  AIDS research and therapy 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Interactions between herbal medicines and prescribed drugs: an updated systematic review.

  Drugs 20090101

• Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.

  HIV clinical trials 20090101

• Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

  BMC infectious diseases 20090101

• A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization.

  Globalization and health 20090101

• Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.

  BMC bioinformatics 20090101

• Evidence for limited genetic compartmentalization of HIV-1 between lung and blood.

  PloS one 20090101

• The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.

  PloS one 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• XVII International AIDS Conference: From Evidence to Action - Clinical and biomedical prevention science.

  Journal of the International AIDS Society 20090101

• Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.

  Antiviral therapy 20090101

• Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

  Antiviral therapy 20090101

• Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.

  Clinical drug investigation 20090101

• Understanding the pharmacokinetics of Coartem.

  Malaria journal 20090101

• Vertebral compression fractures in an HIV-positive patient with steroid-induced Cushing syndrome: a case report.

  Cases journal 20090101

• Development and management of systemic lupus erythematosus in an HIV-infected man with hepatitis C and B co-infection following interferon therapy: a case report.

  Journal of medical case reports 20090101

• High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses.

  Internal medicine (Tokyo, Japan) 20090101

• Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.

  BMC infectious diseases 20090101

• Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.

  BMC bioinformatics 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.

  AIDS research and therapy 20090101

• Update on the use of deferasirox in the management of iron overload.

  Therapeutics and clinical risk management 20090101

• Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

  HIV clinical trials 20090101

• The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia.

  The open virology journal 20090101

• Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.

  Antiviral therapy 20090101

• Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.

  Drug design, development and therapy 20090101

• Factors influencing global antiretroviral procurement prices.

  BMC public health 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model.

  Obstetrics and gynecology international 20090101

• The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review.

  BMC public health 20090101

• Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

  HIV clinical trials 20090101

• Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

  BMC infectious diseases 20090101

• Hepatic profile analyses of tipranavir in Phase II and III clinical trials.

  BMC infectious diseases 20090101

• Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

  AIDS research and therapy 20090101

• Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

  AIDS research and therapy 20090101

• [Desensitization to tipranavir caused by toxicodermia].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Progressive Multifocal Leukoencephalopathy in HIV-Infected Children: A Case Report and Literature Review.

  International journal of pediatrics 20090101

• Conivaptan and its role in the treatment of hyponatremia.

  Drug design, development and therapy 20090101

• Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report.

  Journal of medical case reports 20090101

• Disfiguring molluscum contagiosum in a HIV-positive patient responding to antiretroviral therapy.

  Indian journal of dermatology 20090101

• A comprehensive review of immunosuppression used for liver transplantation.

  Journal of transplantation 20090101

• Liver Injury with Features Mimicking Autoimmune Hepatitis following the Use of Black Cohosh.

  Case reports in medicine 20090101

• Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20090101

• Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.

  HIV clinical trials 20090101

• Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).

  HIV clinical trials 20090101

• Role of multidrug transporters in neurotherapeutics.

  Annals of Indian Academy of Neurology 20090101

• The treatment of chronic hepatitis C virus infection in HIV co-infection.

  European journal of medical research 20090101

• Fatal dual infection with Salmonella and Mycobacterium avium complex infection in a patient with advanced acquired immunodeficiency syndrome: a case report.

  Cases journal 20090101

• Pharmacokinetic Study of a Novel Antihyperlipidemic Agent LM-13765- A Prodrug.

  Indian journal of pharmaceutical sciences 20090101

• Optimal fosamprenavir regimen to prevent lipid abnormalities.

  Acta bio-medica : Atenei Parmensis 20090101

• Drugs impact on CYP-450 enzyme family: A pharmacogenetical study of response variation.

  Indian journal of human genetics 20090101

• Conivaptan: Evidence supporting its therapeutic use in hyponatremia.

  Core evidence 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.

  Core evidence 20090101

• Oral bioavailability and pharmacokinetic study of cetrizine HCl in Iranian healthy volunteers.

  Research in pharmaceutical sciences 20090101

• CCR5 inhibitors: Emerging promising HIV therapeutic strategy.

  Indian journal of sexually transmitted diseases and AIDS 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Lopinavir exposure with an increased dose during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20081215

• Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081215

• Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

  Journal of acquired immune deficiency syndromes (1999) 20081215

• The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.

  Clinical pharmacology and therapeutics 20081201

• Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.

  Clinical pharmacology and therapeutics 20081201

• Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.

  European journal of clinical pharmacology 20081201

• Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.

  Therapeutic drug monitoring 20081201

• Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.

  Antimicrobial agents and chemotherapy 20081201

• Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

  The Journal of antimicrobial chemotherapy 20081201

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir.

  Clinical rheumatology 20081201

• Ritonavir increases CD36, ABCA1 and CYP27 expression in THP-1 macrophages.

  Experimental biology and medicine (Maywood, N.J.) 20081201

• [Iatrogenic Cushing syndrome in an HIV-infected female patient: be careful about interaction inhaled corticosteroids-ritonavir!].

  Presse medicale (Paris, France : 1983) 20081201

• Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.

  The Journal of infection 20081201

• Atazanavir: its role in HIV treatment.

  Expert review of anti-infective therapy 20081201

• [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.

  Journal of acquired immune deficiency syndromes (1999) 20081201

• 96-week data from CASTLE study presented.

  Project Inform perspective 20081201

• Darunavir now approved for use in treatment-naive patients.

  AIDS clinical care 20081201

• Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.

  HIV/AIDS policy & law review 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• [Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Monotherapy in treatment-naïve patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [The 'induction-maintenance' strategy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy. Possible indications].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy for the treatment of HIV-1 infection: the emergence of resistance].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Penetration in reservoirs].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in treatment-naive patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in simplification regimens].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Efficacy of atazanavir in rescue therapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Viral resistance and genetic barrier of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Clinical utility of atazanavir].

  Enfermedades infecciosas y microbiologia clinica 20081201

• Early antiretroviral therapy and mortality among HIV-infected infants.

  The New England journal of medicine 20081120

• Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081115

• Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

  AIDS (London, England) 20081112

• Five years later: re-examining the financial burden of boosting with Norvir.

  AIDS (London, England) 20081112

• Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.

  AIDS (London, England) 20081112

• Evaluation of an International Pharmacopoeia method for the analysis of ritonavir by liquid chromatography.

  Journal of pharmaceutical and biomedical analysis 20081104

• TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs.

  Biomaterials 20081101

• Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20081101

• Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.

  International journal of clinical practice 20081101

• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  The Journal of infectious diseases 20081101

• Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

  The Pediatric infectious disease journal 20081101

• Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20081101

• Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20081101

• Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes.

  PLoS computational biology 20081101

• Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.

  Current HIV research 20081101

• Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.

  AIDS patient care and STDs 20081101

• 96-week CASTLE data show similar efficacy results.

  AIDS patient care and STDs 20081101

• [Pharmacokinetics and interactions of raltegravir].

  Enfermedades infecciosas y microbiologia clinica 20081101

• The role of novel biomarkers of cardiovascular disease in chronic kidney disease: focus on adiponectin and leptin.

  Current cardiology reviews 20081101

• Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.

  European journal of medical research 20081027

• Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors.

  Journal of theoretical biology 20081021

• Doxorubicin-induced hyperpigmentation.

  Dermatology online journal 20081015

• Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20081009

• Rapid screening and characterization of drug metabolites using a multiple ion monitoring-dependent MS/MS acquisition method on a hybrid triple quadrupole-linear ion trap mass spectrometer.

  Journal of mass spectrometry : JMS 20081001

• Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.

  Pharmaceutical research 20081001

• Maraviroc: in vitro assessment of drug-drug interaction potential.

  British journal of clinical pharmacology 20081001

• Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response.

  Obesity (Silver Spring, Md.) 20081001

• Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications.

  Therapeutic drug monitoring 20081001

• Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

  AIDS (London, England) 20081001

• Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand.

  Journal of acquired immune deficiency syndromes (1999) 20081001

• Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

  AIDS research and human retroviruses 20081001

• Changes to Norvir labeling.

  AIDS patient care and STDs 20081001

• FDA notifications. Norvir label changes approved.

  AIDS alert 20081001

• Is Bayh-Dole good for developing countries? Lessons from the US experience.

  PLoS biology 20081001

• [Chemical characteristics, mechanism of action and antiviral activity of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in treatment-naïve patients. The ARTEMIS study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir as first-line therapy. The TITAN study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Safety and tolerability of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Pharmacological interactions with darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

  Clinical pharmacology and therapeutics 20081001

• Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

  Clinical pharmacology and therapeutics 20081001

• HIV-protease inhibitors block the enzymatic activity of purified Ste24p.

  Biochemical and biophysical research communications 20080919

• Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.

  AIDS (London, England) 20080912

• Structure-activity relationship study on anti-HIV 6-desfluoroquinolones.

  Journal of medicinal chemistry 20080911

• The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.

  The Journal of antimicrobial chemotherapy 20080901

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

  Expert opinion on pharmacotherapy 20080901

• Heat-stable Norvir tablet provides similar drug levels to capsule.

  AIDS patient care and STDs 20080901

• Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.

  The AIDS reader 20080901

• HIV infection in the elderly.

  Clinical interventions in aging 20080901

• Heat stable formulation of Norvir appears likely.

  Project Inform perspective 20080901

• Initial treatment of HIV-1 infection.

  The New England journal of medicine 20080828

• Initial treatment of HIV-1 infection.

  The New England journal of medicine 20080828

• A king in the CASTLE? Optimum initial HIV protease inhibitor.

  Lancet (London, England) 20080823

• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

  Lancet (London, England) 20080823

• Noninferiority and lopinavir/ritonavir monotherapy trials.

  AIDS (London, England) 20080820

• No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080815

• Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20080815

• Metabolic changes in protease inhibitor-naive patients treated for 1 year with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20080815

• Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

  Journal of the American College of Cardiology 20080812

• CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.

  Clinical pharmacology and therapeutics 20080801

• CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

  European journal of clinical pharmacology 20080801

• Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.

  British journal of clinical pharmacology 20080801

• Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

  Antimicrobial agents and chemotherapy 20080801

• Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080801

• Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.

  Journal of clinical pharmacy and therapeutics 20080801

• Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?

  AIDS research and human retroviruses 20080801

• Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

  Therapeutic drug monitoring 20080801

• Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.

  International journal of STD & AIDS 20080801

• Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.

  International journal of STD & AIDS 20080801

• Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Kaletra oral solution: modification of confusing label: packaging. an infant died in France.

  Prescrire international 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

  AIDS (London, England) 20080731

• A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

  The Journal of infectious diseases 20080715

• Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes.

  AIDS (London, England) 20080711

• Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

  Clinical pharmacology and therapeutics 20080701

• HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

• Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature.

  HIV medicine 20080701

• Lipoprotein(a) in patients initiating antiretroviral therapy.

  HIV medicine 20080701

• A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.

  Journal of virological methods 20080701

• Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing.

  The Journal of antimicrobial chemotherapy 20080701

• Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

  The Journal of infectious diseases 20080701

• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080701

• Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

  The Pediatric infectious disease journal 20080701

• Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study.

  Journal of acquired immune deficiency syndromes (1999) 20080701

• Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.

  Pharmacotherapy 20080701

• Possible antiretroviral therapy-warfarin drug interaction.

  Pharmacotherapy 20080701

• Induction effects of ritonavir: implications for drug interactions.

  The Annals of pharmacotherapy 20080701

• Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.

  Molecular cancer therapeutics 20080701

• Invirase package insert updated.

  AIDS patient care and STDs 20080701

• Possible pharmacokinetic interaction involving ritonavir and docetaxel in a patient with Kaposi's sarcoma.

  AIDS (London, England) 20080619

• Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080615

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Solution structure of HIV-1 protease flaps probed by comparison of molecular dynamics simulation ensembles and EPR experiments.

  Journal of the American Chemical Society 20080611

• Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

  British journal of cancer 20080603

• HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

  The Journal of clinical investigation 20080602

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.

  Clinical pharmacology and therapeutics 20080601

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• [Drug-related neuropathies: analysis of the French Adverse Drug Reaction Database 1995-2005].

  Presse medicale (Paris, France : 1983) 20080601

• Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

  The Journal of antimicrobial chemotherapy 20080601

• Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

  The Journal of antimicrobial chemotherapy 20080601

• Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

  The Journal of antimicrobial chemotherapy 20080601

• First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.

  The Journal of antimicrobial chemotherapy 20080601

• Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

  The Journal of antimicrobial chemotherapy 20080601

• Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.

  The Journal of antimicrobial chemotherapy 20080601

• Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study.

  Infection 20080601

• Determination of tacrolimus in rabbit aqueous humor by liquid chromatography-electrospray ionization tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080601

• Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

  AIDS research and human retroviruses 20080601

• Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz.

  AIDS research and human retroviruses 20080601

• Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.

  Biological & pharmaceutical bulletin 20080601

• Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

  Therapeutic drug monitoring 20080601

• Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.

  Journal of cardiovascular pharmacology 20080601

• Screening and Management of HIV-2-Infected Individuals in Northern Italy.

  AIDS patient care and STDs 20080601

• Darunavir: after multiple antiretroviral treatment failure: another option.

  Prescrire international 20080601

• Pharmacogenomics of antiretrovirals.

  Recent patents on anti-infective drug discovery 20080601

• Atorvastatin and cardiovascular risk in the elderly--patient considerations.

  Clinical interventions in aging 20080601

• Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.

  Current HIV research 20080601

• Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms.

  AIDS (London, England) 20080531

• Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.

  Journal of medicinal chemistry 20080522

• Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry.

  Analytical chemistry 20080515

• Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Class-sparing regimens for initial treatment of HIV-1 infection.

  The New England journal of medicine 20080515

• Initial treatment for HIV infection--an embarrassment of riches.

  The New England journal of medicine 20080515

• High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.

  AIDS (London, England) 20080511

• Ritonavir and disulfiram may be synergistic in lowering active interleukin-18 levels in acute pancreatitis, and thereby hasten recovery.

  JOP : Journal of the pancreas 20080508

• Dog model with implanted pump to test boosters for antiretroviral medication.

  International journal of pharmaceutics 20080501

• Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.

  British journal of clinical pharmacology 20080501

• Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

  Antimicrobial agents and chemotherapy 20080501

• Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.

  HIV medicine 20080501

• Studies on flexibility and binding affinity of Asp25 of HIV-1 protease mutants.

  International journal of biological macromolecules 20080501

• Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

  The Pediatric infectious disease journal 20080501

• Complexity of interactions between voriconazole and antiretroviral agents.

  The Annals of pharmacotherapy 20080501

• Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

  Journal of clinical pharmacology 20080501

• Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir.

  Current HIV research 20080501

• Kaletra lower-strength pediatric tablet approved in Europe.

  AIDS patient care and STDs 20080501

• [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].

  MMW Fortschritte der Medizin 20080428

• Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.

  Journal of computational chemistry 20080415

• Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20080415

• Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

  Journal of acquired immune deficiency syndromes (1999) 20080415

• A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.

  The Journal of biological chemistry 20080411

• Evaluation of change in CD4+ cell counts in AIDS clinical trials.

  Statistical methods in medical research 20080401

• Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.

  Clinical pharmacology and therapeutics 20080401

• Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.

  Journal of cellular biochemistry 20080401

• Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

  Antimicrobial agents and chemotherapy 20080401

• Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.

  The Journal of antimicrobial chemotherapy 20080401

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.

  Pediatrics 20080401

• Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.

  British journal of clinical pharmacology 20080401

• Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

  HIV medicine 20080401

• A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules.

  International journal of clinical pharmacology and therapeutics 20080401

• An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.

  AIDS patient care and STDs 20080401

• Protease inhibitor resistance update: where are we now?

  AIDS patient care and STDs 20080401

• Fluticasone furoate nasal spray in the treatment of allergic rhinitis.

  Therapeutics and clinical risk management 20080401

• Raltegravir: first in class HIV integrase inhibitor.

  Therapeutics and clinical risk management 20080401

• Enfuvirtide antiretroviral therapy in HIV-1 infection.

  Therapeutics and clinical risk management 20080401

• Association of antiretroviral therapy with fibrinogen levels in HIV-infection.

  AIDS (London, England) 20080330

• Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir/ritonavir poisoning in a HIV-positive patient.

  AIDS (London, England) 20080330

• Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

  Biopharmaceutics & drug disposition 20080301

• A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor.

  Drug metabolism and disposition: the biological fate of chemicals 20080301

• Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080301

• Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

  Pharmacotherapy 20080301

• CASTLE study showed similar efficacy.

  AIDS patient care and STDs 20080301

• [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].

  Enfermedades infecciosas y microbiologia clinica 20080301

• Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080301

• Tumor targeting using liposomal antineoplastic drugs.

  International journal of nanomedicine 20080301

• Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.

  TreatmentUpdate 20080301

• The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.

  Journal of HIV therapy 20080301

• The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

  Clinical pharmacology and therapeutics 20080201

• Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

  Journal of acquired immune deficiency syndromes (1999) 20080201

• Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20080201

• Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

  Antimicrobial agents and chemotherapy 20080201

• Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.

  HIV medicine 20080201

• [Thromboembolic events at the time of highly active antiretroviral therapies against human immunodeficiency virus].

  La Revue de medecine interne 20080201

• Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

  Current medical research and opinion 20080201

• A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome.

  Nature clinical practice. Nephrology 20080201

• Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.

  Fundamental & clinical pharmacology 20080201

• Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.

  AIDS patient care and STDs 20080201

• Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20080201

• Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.

  The AIDS reader 20080201

• Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.

  Journal of chemotherapy (Florence, Italy) 20080201

• HIV therapy, metabolic syndrome, and cardiovascular risk.

  Current atherosclerosis reports 20080201

• Atazanavir/ritonavir: a review of its use in HIV therapy.

  Drugs of today (Barcelona, Spain : 1998) 20080201

• Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

  Therapeutics and clinical risk management 20080201

• Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.

  AIDS (London, England) 20080130

• Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

  AIDS (London, England) 20080130

• Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.

  AIDS (London, England) 20080130

• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

  AIDS (London, England) 20080111

• Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

  AIDS (London, England) 20080111

• The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.

  Clinical pharmacology and therapeutics 20080101

• Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

  The Journal of antimicrobial chemotherapy 20080101

• Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.

  Autophagy 20080101

• Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

  The Journal of antimicrobial chemotherapy 20080101

• Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial.

  Journal of clinical epidemiology 20080101

• Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.

  Journal of clinical pharmacology 20080101

• Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.

  AIDS patient care and STDs 20080101

• Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.

  Pharmacotherapy 20080101

• Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20080101

• Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080101

• Increased risk of bleeding with the use of tipranavir boosted with ritonavir in haemophilic patients.

  Haemophilia : the official journal of the World Federation of Hemophilia 20080101

• Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma.

  Infectious agents and cancer 20080101

• Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.

  HIV clinical trials 20080101

• Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.

  Retrovirology 20080101

• Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report.

  Annals of clinical microbiology and antimicrobials 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.

  Rapid communications in mass spectrometry : RCM 20080101

• Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

  Journal of neurovirology 20080101

• Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.

  BMC neuroscience 20080101

• Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

  Retrovirology 20080101

• Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy.

  Retrovirology 20080101

• Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).

  TreatmentUpdate 20080101

• Anti-HIV agents. A trial of Kaletra monotherapy.

  TreatmentUpdate 20080101

• Anti-HIV agents. Monotherapy studies--points to consider.

  TreatmentUpdate 20080101

• Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation.

  Virology journal 20080101

• Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation.

  BMC musculoskeletal disorders 20080101

• Efficacy and safety of once-daily regimens in the treatment of HIV infection.

  Drugs 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Acute renal failure in an AIDS patient on tenofovir: a case report.

  Journal of medical case reports 20080101

• Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.

  PloS one 20080101

• Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

  AIDS reviews 20080101

• Darunavir: pharmacokinetics and drug interactions.

  Antiviral therapy 20080101

• Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens.

  Antiviral therapy 20080101

• Proteochemometric modeling of HIV protease susceptibility.

  BMC bioinformatics 20080101

• Ugandan children receive lower-strength Aluvia.

  AIDS patient care and STDs 20080101

• Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.

  HIV clinical trials 20080101

• Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.

  HIV clinical trials 20080101

• Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis.

  Journal of postgraduate medicine 20080101

• Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

  Antiviral therapy 20080101

• Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.

  HIV clinical trials 20080101

• Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.

  HIV clinical trials 20080101

• Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

  Clinical pharmacokinetics 20080101

• Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

  Antiviral therapy 20080101

• Tipranavir: a review of its use in the management of HIV infection.

  Drugs 20080101

• Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.

  Clinical drug investigation 20080101

• Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis: is co-trimoxazole the culprit?

  Journal of postgraduate medicine 20080101

• Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes.

  PloS one 20080101

• P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors.

  Ethnicity & disease 20080101

• Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

  PloS one 20080101

• Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.

  Antiviral therapy 20080101

• Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.

  Antiviral therapy 20080101

• Medical management of human immunodeficiency virus infection.

  Indian journal of ophthalmology 20080101

• Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.

  BMC complementary and alternative medicine 20080101

• Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

  HIV clinical trials 20080101

• Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.

  HIV clinical trials 20080101

• 'White coat compliance' limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

  HIV clinical trials 20080101

• Predictive validity of a brief antiretroviral adherence index: retrospective cohort analysis under conditions of repetitive administration.

  AIDS research and therapy 20080101

• Same patient, new stone composition: amprenavir urinary stone.

  Antiviral therapy 20080101

• Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study.

  BMC pediatrics 20080101

• Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

  Clinical pharmacokinetics 20080101

• Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

  AIDS research and therapy 20080101

• Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

  AIDS reviews 20080101

• Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy.

  PloS one 20080101

• Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

  Antiviral therapy 20080101

• Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.

  Antiviral therapy 20080101

• [Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20080101

• Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

  PloS one 20080101

• Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.

  The open AIDS journal 20080101

• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

  BMC infectious diseases 20080101

• Double-boosted protease inhibitor antiretroviral regimens: what role?

  Drugs 20080101

• Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

  PloS one 20080101

• 25 years of HIV-1 research - progress and perspectives.

  BMC medicine 20080101

• Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens.

  HIV clinical trials 20080101

• Ability of online drug databases to assist in clinical decision-making with infectious disease therapies.

  BMC infectious diseases 20080101

• Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.

  Retrovirology 20080101

• Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

  Antiviral therapy 20080101

• Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report.

  Journal of medical case reports 20080101

• Microemulsions: a novel approach to enhanced drug delivery.

  Recent patents on drug delivery & formulation 20080101

• No residual activity of raltegravir after development of 148 complex mutations in vivo.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

  Antiviral therapy 20080101

• Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

  Antiviral therapy 20080101

• Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.

  HIV clinical trials 20080101

• Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

  HIV clinical trials 20080101

• PH-induced nanosegregation of ritonavir to lyotropic liquid crystal of higher solubility than crystalline polymorphs.

  Molecular pharmaceutics 20080101

• Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina.

  Journal of the International AIDS Society 20080101

• Raltegravir in the management of HIV-infected patients.

  Drug design, development and therapy 20080101

• Fexofenadine hydrochloride in the treatment of allergic disease: a review.

  Journal of asthma and allergy 20080101

• Neuroprotective effects of garlic a review.

  The Libyan journal of medicine 20080101

• [Dietary recommendations with practical examples of menus for people living with HIV/AIDS in sub-Saharan Africa].

  The Pan African medical journal 20080101

• Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005.

  The Pan African medical journal 20080101

• Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

  Infection and drug resistance 20080101

• Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071215

• Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.

  The Journal of infectious diseases 20071215

• Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071215

• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

  Drug and alcohol dependence 20071201

• Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.

  Antiviral research 20071201

• Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20071201

• Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials.

  The Journal of antimicrobial chemotherapy 20071201

• Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).

  Eye (London, England) 20071201

• Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

  Therapeutic drug monitoring 20071201

• Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.

  Therapeutic drug monitoring 20071201

• Modulation of proteasome activity by vitamin E in THP-1 monocytes.

  IUBMB life 20071201

• Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

  AIDS patient care and STDs 20071201

• A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.

  AIDS research and human retroviruses 20071201

• Fatal Streptococcus equi subsp. ruminatorum infection in a man.

  Emerging infectious diseases 20071201

• Essential medical issues related to HIV in dentistry.

  Journal (Canadian Dental Association) 20071201

• Lower dose of ritonavir approved for use with fosamprenavir.

  AIDS clinical care 20071201

• Review of tenofovir-emtricitabine.

  Therapeutics and clinical risk management 20071201

• The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.

  Statistics in medicine 20071130

• Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

  AIDS (London, England) 20071130

• Pricing. Pharmacies file Norvir suits against Abbott.

  AIDS policy & law 20071116

• HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.

  AIDS (London, England) 20071112

• Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.

  British journal of clinical pharmacology 20071101

• Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

  Journal of medical virology 20071101

• Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.

  Clinical and vaccine immunology : CVI 20071101

• Modeling metabolic effects of the HIV protease inhibitor ritonavir in vitro.

  The American journal of pathology 20071101

• Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

  The Journal of antimicrobial chemotherapy 20071101

• Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

  Basic & clinical pharmacology & toxicology 20071101

• Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

  HIV medicine 20071101

• Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.

  HIV medicine 20071101

• Relative antiviral efficacy should not be inferred from cross-trial comparisons.

  HIV medicine 20071101

• Scutellaria baicalensis and a constituent flavonoid, baicalein, attenuate ritonavir-induced gastrointestinal side-effects.

  The Journal of pharmacy and pharmacology 20071101

• Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

  PLoS medicine 20071101

• Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

  Clinical therapeutics 20071101

• Unusual causes of Cushing's syndrome.

  Arquivos brasileiros de endocrinologia e metabologia 20071101

• Aptivus capsules granted full FDA approval.

  AIDS patient care and STDs 20071101

• Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.

  AIDS (London, England) 20071018

• Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.

  AIDS (London, England) 20071018

• The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.

  Clinical pharmacology and therapeutics 20071001

• Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

  European journal of clinical pharmacology 20071001

• Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.

  The Journal of antimicrobial chemotherapy 20071001

• Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.

  European journal of clinical pharmacology 20071001

• Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues.

  The Journal of antimicrobial chemotherapy 20071001

• Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.

  Genomics 20071001

• The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20071001

• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

  Therapeutic drug monitoring 20071001

• Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

  Therapeutic drug monitoring 20071001

• Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.

  PLoS pathogens 20071001

• Darunavir phase 3 study data released.

  AIDS patient care and STDs 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Tipranavir: a new option for the treatment of drug-resistant HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915

• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

  AIDS (London, England) 20070912

• Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

  AIDS (London, England) 20070912

• Efavirenz urolithiasis.

  AIDS (London, England) 20070912

• Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

  Archives of internal medicine 20070910

• Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

  Journal of medicinal chemistry 20070906

• Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

  British journal of clinical pharmacology 20070901

• Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.

  Antimicrobial agents and chemotherapy 20070901

• Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

  Journal of acquired immune deficiency syndromes (1999) 20070901

• Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20070901

• Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• Predicting HIV care costs using CD4 counts from clinical trials.

  The American journal of managed care 20070901

• Patient preferences among third agent HIV medications: a US and German perspective.

  AIDS care 20070901

• Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.

  The Journal of pharmacy and pharmacology 20070901

• Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.

  Journal of acquired immune deficiency syndromes (1999) 20070901

• Eszopiclone for late-life insomnia.

  Clinical interventions in aging 20070901

• Pharmacologic management of overactive bladder.

  Clinical interventions in aging 20070901

• Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.

  AIDS (London, England) 20070820

• Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals.

  Immunology letters 20070815

• Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Interaction between lopinavir/ritonavir and warfarin.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070814

• Identification and characterization of an aspartyl protease from Cryptococcus neoformans.

  FEBS letters 20070807

• In vitro evaluation of human cytochrome P450 and P-glycoprotein-mediated metabolism of some phytochemicals in extracts and formulations of African potato.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20070801

• Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.

  Bioorganic & medicinal chemistry letters 20070801

• Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.

  Journal of acquired immune deficiency syndromes (1999) 20070801

• Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.

  The Journal of antimicrobial chemotherapy 20070801

• Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.

  Journal of clinical pharmacology 20070801

• Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.

  Journal of acquired immune deficiency syndromes (1999) 20070801

• Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.

  Journal of acquired immune deficiency syndromes (1999) 20070801

• Darunavir: a second-generation protease inhibitor.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070801

• Hair loss induced by lopinavir-ritonavir.

  Pharmacotherapy 20070801

• Darunavir (TMC114): a new HIV-1 protease inhibitor.

  Expert opinion on pharmacotherapy 20070801

• Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.

  Prescrire international 20070801

• Aluvia tablet approved in 19 African countries.

  AIDS patient care and STDs 20070801

• Tipranavir demonstrates potent and durable treatment response in HIV-positive women.

  AIDS patient care and STDs 20070801

• Clinical studies with oral lipid based formulations of poorly soluble compounds.

  Therapeutics and clinical risk management 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients.

  AIDS (London, England) 20070731

• Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.

  AIDS (London, England) 20070731

• Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.

  European journal of medical research 20070726

• Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

  The Journal of infectious diseases 20070715

• [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].

  Medicina clinica 20070714

• Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.

  AIDS (London, England) 20070711

• Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.

  AIDS (London, England) 20070711

• Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

  Lancet (London, England) 20070707

• Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects.

  European journal of obstetrics, gynecology, and reproductive biology 20070701

• Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety.

  Pharmaceutical research 20070701

• Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.

  Journal of acquired immune deficiency syndromes (1999) 20070701

• Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006.

  The Journal of antimicrobial chemotherapy 20070701

• Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.

  The Annals of pharmacotherapy 20070701

• Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection.

  The Journal of infectious diseases 20070701

• Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells.

  The American journal of pathology 20070701

• Clinical ritonavir and lopinavir hypersensitivity confirmed by a specific in vitro cellular allergen stimulation test.

  Current HIV research 20070701

• Optimal timing and duration of induction therapy for HIV-1 infection.

  PLoS computational biology 20070701

• Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.

  The Journal of pharmacy and pharmacology 20070701

• Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.

  AIDS patient care and STDs 20070701

• Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.

  Journal of drugs in dermatology : JDD 20070701

• Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.

  The new microbiologica 20070701

• Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data.

  International journal of pharmaceutics 20070629

• The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.

  AIDS (London, England) 20070619

• Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.

  AIDS (London, England) 20070619

• Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.

  AIDS (London, England) 20070619

• Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects.

  AIDS (London, England) 20070619

• Alopecia associated with ritonavir-boosted atazanavir therapy.

  AIDS (London, England) 20070619

• Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir.

  Hematological oncology 20070601

• A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20070601

• HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.

  Biochemical pharmacology 20070601

• Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20070601

• Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants.

  Antimicrobial agents and chemotherapy 20070601

• The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601

• Therapeutic issues in HIV/HCV-coinfected patients.

  Journal of viral hepatitis 20070601

• Why do patients fail HIV therapy?

  International journal of clinical practice 20070601

• Access to drugs: the case of Abbott in Thailand.

  The Lancet. Infectious diseases 20070601

• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

  Journal of acquired immune deficiency syndromes (1999) 20070601

• Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.

  Expert opinion on drug metabolism & toxicology 20070601

• Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.

  Pharmacotherapy 20070601

• Fosamprenavir calcium plus ritonavir for HIV infection.

  Expert review of anti-infective therapy 20070601

• Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment.

  Infection 20070601

• Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent.

  AIDS patient care and STDs 20070601

• Pharmacologic treatment of SARS: current knowledge and recommendations.

  Annals of the Academy of Medicine, Singapore 20070601

• HPV oral infection. Case report of an HIV-positive Nigerian sex worker.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20070601

• Antiretroviral pharmacokinetic profile: a review of sex differences.

  Gender medicine 20070601

• Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

  Metabolic syndrome and related disorders 20070601

• Effect of patient-specific factors on weekly warfarin dose.

  Therapeutics and clinical risk management 20070601

• Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.

  AIDS (London, England) 20070531

• Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.

  AIDS (London, England) 20070531

• Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.

  AIDS (London, England) 20070531

• Response to 'Nifedipine-lopinavir/ritonavir severe interaction: a case report'.

  AIDS (London, England) 20070531

• Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.

  The Journal of infectious diseases 20070515

• Steady-state lopinavir levels in third trimester of pregnancy.

  AIDS (London, England) 20070511

• Efficient induction of HIV-1 replication in latently infected cells through contact with CD4+ T cells: involvement of NF-kappaB activation.

  Virology 20070510

• Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20070501

• CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir.

  Clinical pharmacology and therapeutics 20070501

• Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

  The Journal of antimicrobial chemotherapy 20070501

• Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

  Pediatrics 20070501

• Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20070501

• HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo.

  Apoptosis : an international journal on programmed cell death 20070501

• HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Monotherapy with lopinavir/ritonavir.

  Expert opinion on investigational drugs 20070501

• Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

  HIV medicine 20070501

• Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.

  HIV medicine 20070501

• Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.

  HIV medicine 20070501

• Multidrug resistance proteins affect drug transmission across the placenta.

  American journal of obstetrics and gynecology 20070501

• Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role?

  Expert opinion on pharmacotherapy 20070501

• Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells.

  Mycoses 20070501

• Abbott agrees to expand access to Kaletra/Aluvia.

  AIDS patient care and STDs 20070501

• [Number and nature of drug interactions concerning antineoplastic drugs].

  Bulletin du cancer 20070501

• Improving access to second-line antiretrovirals.

  Lancet (London, England) 20070421

• Darunavir: promising initial results.

  Lancet (London, England) 20070407

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

  Lancet (London, England) 20070407

• Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

  The Journal of infection 20070401

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.

  Journal of acquired immune deficiency syndromes (1999) 20070401

• The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

  Journal of acquired immune deficiency syndromes (1999) 20070401

• HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts.

  Antiviral research 20070401

• Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.

  Antimicrobial agents and chemotherapy 20070401

• Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

  The Journal of antimicrobial chemotherapy 20070401

• Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

  The Journal of infectious diseases 20070401

• Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors.

  Microbes and infection 20070401

• Atazanavir: simplicity and convenience in different scenarios.

  Expert opinion on pharmacotherapy 20070401

• Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.

  European journal of haematology 20070401

• Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA.

  Journal of clinical pharmacy and therapeutics 20070401

• The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

  Journal of clinical pharmacology 20070401

• Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.

  Biological & pharmaceutical bulletin 20070401

• Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

  Therapeutic drug monitoring 20070401

• Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.

  Expert opinion on pharmacotherapy 20070401

• Lopinavir/ritonavir: appraisal of its use in HIV therapy.

  Drugs of today (Barcelona, Spain : 1998) 20070401

• Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.

  AIDS patient care and STDs 20070401

• Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

  Vascular health and risk management 20070401

• Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.

  The new microbiologica 20070401

• Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

  AIDS (London, England) 20070330

• Antimalarial activity of sera from subjects taking HIV protease inhibitors.

  AIDS (London, England) 20070330

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.

  AIDS (London, England) 20070312

• Bioavailability and pharmacokinetic model for ritonavir in the rat.

  Journal of pharmaceutical sciences 20070301

• Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART.

  American journal of physiology. Endocrinology and metabolism 20070301

• Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.

  Journal of acquired immune deficiency syndromes (1999) 20070301

• [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].

  Medecine et maladies infectieuses 20070301

• Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

  The Journal of antimicrobial chemotherapy 20070301

• Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070301

• Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

  HIV medicine 20070301

• Antiretroviral management of treatment-naive patients.

  Infectious disease clinics of North America 20070301

• [Two year use of Telzir: what are the perspectives?].

  Medecine et maladies infectieuses 20070301

• Update on the use of dutasteride in the management of benign prostatic hypertrophy.

  Clinical interventions in aging 20070301

• Drug reimportation practices in the United States.

  Therapeutics and clinical risk management 20070301

• Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

  AIDS (London, England) 20070219

• Iatrogenic Cushing's syndrome in a adolescent with AIDSs on ritonavir and inhaled fluticasone. Case report and literature review.

  AIDS (London, England) 20070219

• Acute pancreatitis caused by tipranavir/ritonavir-induced hypertriglyceridaemia.

  AIDS (London, England) 20070219

• Validation of an HIV-1 inactivation protocol that is compatible with intracellular drug analysis by mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070215

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20070201

• Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers.

  Journal of clinical pharmacology 20070201

• Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.

  AIDS research and human retroviruses 20070201

• Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

  Expert review of anti-infective therapy 20070201

• Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.

  AJNR. American journal of neuroradiology 20070201

• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.

  Therapeutic drug monitoring 20070201

• Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.

  AIDS patient care and STDs 20070201

• HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.

  AIDS research and human retroviruses 20070201

• Dose reduction effective in alleviating symptoms of saquinavir toxicity.

  International journal of STD & AIDS 20070201

• Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections.

  Emerging infectious diseases 20070201

• Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20070201

• Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

  AIDS (London, England) 20070130

• Directed reductive amination of beta-hydroxy-ketones: convergent assembly of the ritonavir/lopinavir core.

  Organic letters 20070118

• Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.

  AIDS (London, England) 20070111

• Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

  AIDS (London, England) 20070102

• Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.

  AIDS (London, England) 20070102

• Nifedipine-lopinavir/ritonavir severe interaction: a case report.

  AIDS (London, England) 20070102

• Hyponatraemia associated with lopinavir--ritonavir?

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20070101

• Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry.

  Clinica chimica acta; international journal of clinical chemistry 20070101

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• In silico prediction of pregnane X receptor activators by machine learning approaches.

  Molecular pharmacology 20070101

• A calorimetric investigation of thermodynamic and molecular mobility contributions to the physical stability of two pharmaceutical glasses.

  Journal of pharmaceutical sciences 20070101

• Evaluation of 384-well formatted sample preparation technologies for regulated bioanalysis.

  Rapid communications in mass spectrometry : RCM 20070101

• The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis.

  International journal of antimicrobial agents 20070101

• Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

  Clinical drug investigation 20070101

• Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

  Clinical pharmacology and therapeutics 20070101

• Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children.

  The Pediatric infectious disease journal 20070101

• Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

  Clinical pharmacokinetics 20070101

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.

  AIDS research and human retroviruses 20070101

• Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).

  AIDS research and therapy 20070101

• Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.

  HIV medicine 20070101

• Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report.

  AIDS research and therapy 20070101

• Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20070101

• Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

  BMC pediatrics 20070101

• HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

  PloS one 20070101

• In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.

  Retrovirology 20070101

• The clinical pharmacokinetics of escitalopram.

  Clinical pharmacokinetics 20070101

• Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.

  HIV clinician 20070101

• Immunologic, virologic, and neuropsychologic responses in human immunodeficiency virus-infected children receiving their first highly active antiretroviral therapy regimen.

  Viral immunology 20070101

• Gender-specific effects of HIV protease inhibitors on body mass in mice.

  AIDS research and therapy 20070101

• Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.

  Journal of medical case reports 20070101

• Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.

  Antiviral therapy 20070101

• Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

  Antiviral therapy 20070101

• Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

  Antiviral therapy 20070101

• Antigen-presenting particle technology using inactivated surface-engineered viruses: induction of immune responses against infectious agents.

  Retrovirology 20070101

• Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone.

  HIV clinical trials 20070101

• Infections and immunosuppression as specific problems in a HIV + patient transplanted for end-stage alcoholic cirrhosis.

  Acta chirurgica Belgica 20070101

• 48-week study results show DRV's staying power.

  IAPAC monthly 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts.

  AIDS research and therapy 20070101

• Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

  BMC infectious diseases 20070101

• Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

  Clinical drug investigation 20070101

• Anti-HIV agents. Maraviroc--coming soon.

  TreatmentUpdate 20070101

• Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy.

  PloS one 20070101

• Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.

  Drugs in R&D 20070101

• Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.

  AIDS research and therapy 20070101

• Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir.

  Antiviral chemistry & chemotherapy 20070101

• X-ray structure of HIV-1 protease tethered dimer complexed to ritonavir.

  Protein and peptide letters 20070101

• HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.

  AIDS research and therapy 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.

  Antiviral therapy 20070101

• Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.

  Antiviral therapy 20070101

• Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.

  Scandinavian journal of infectious diseases 20070101

• Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.

  Antiviral therapy 20070101

• Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

  Antiviral therapy 20070101

• Clinical pharmacokinetics of darunavir.

  Clinical pharmacokinetics 20070101

• High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.

  HIV clinical trials 20070101

• Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.

  HIV clinical trials 20070101

• Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

  Clinical pharmacokinetics 20070101

• Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

  Antiviral therapy 20070101

• Extended administration of the association of zidovudine plus ritonavir during rat pregnancy: maternal and fetal effects.

  Clinical and experimental obstetrics & gynecology 20070101

• Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

  AIDS research and therapy 20070101

• Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

  HIV clinical trials 20070101

• Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.

  HIV clinical trials 20070101

• Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.

  Antiviral therapy 20070101

• Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.

  Clinical drug investigation 20070101

• Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

  BMC public health 20070101

• Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

  Cost effectiveness and resource allocation : C/E 20070101

• Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women.

  HIV clinical trials 20070101

• Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

  Current medicinal chemistry 20070101

• Isothiazole derivatives as antiviral agents.

  Antiviral chemistry & chemotherapy 20070101

• Patented small molecule inhibitors in the ubiquitin proteasome system.

  BMC biochemistry 20070101

• [Interruption to treatment with combined lopinavir/ritonavir therapy in HIV positive patients].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

• [Intestinal microbiota of individuals who suffered occupational accidents with biological materials and underwent antiretroviral prophylaxis].

  Revista da Sociedade Brasileira de Medicina Tropical 20070101

• Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.

  Antiviral therapy 20070101

• Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

  Antiviral therapy 20070101

• Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.

  Antiviral therapy 20070101

• [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20070101

• Alpha-Tocopherol counteracts ritonavir-induced proinflammatory cytokines expression in differentiated THP-1 cells.

  BioFactors (Oxford, England) 20070101

• Drug interactions of tipranavir, a new HIV protease inhibitor.

  Drug metabolism letters 20070101

• The 16th International Conference on AIDS: Will It Leave a Legacy?

  Journal of the International AIDS Society 20070101

• Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.

  Core evidence 20070101

• Maraviroc: the evidence for its potential in the management of HIV.

  Core evidence 20070101

• Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.

  Core evidence 20070101

• NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.

  British journal of cancer 20061218

• Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215

• Tipranavir without ritonavir does not acutely induce peripheral insulin resistance in a rodent model.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Chaperonin 10 for rheumatoid arthritis.

  Lancet (London, England) 20061202

• Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.

  American journal of physiology. Cell physiology 20061201

• HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.

  American journal of physiology. Gastrointestinal and liver physiology 20061201

• Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury.

  Journal of acquired immune deficiency syndromes (1999) 20061201

• Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.

  Journal of medical virology 20061201

• Tipranavir: new drug. HIV protease inhibitor. A last resort.

  Prescrire international 20061201

• Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

  Clinical pharmacology and therapeutics 20061201

• Intracranial hemorrhage with Aptivu.

  AIDS patient care and STDs 20061201

• Meeting report. Report from ICAAC.

  AIDS clinical care 20061201

• [Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20061201

• Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence.

  Clinical interventions in aging 20061201

• The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.

  AIDS (London, England) 20061128

• Measuring below the bar: what is it telling us?

  AIDS (London, England) 20061128

• Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061115

• Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061115

• Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.

  Antiviral research 20061101

• In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

  Antimicrobial agents and chemotherapy 20061101

• The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20061101

• Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.

  Research in microbiology 20061101

• Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.

  Journal of acquired immune deficiency syndromes (1999) 20061101

• Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20061101

• Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).

  The Journal of infectious diseases 20061101

• P-glycoprotein effects of cyclic urea HIV protease inhibitor DMP 323 in competitional absorption studies.

  Archiv der Pharmazie 20061101

• Stability of ritonavir soft capsule formulation in patients with and without a refrigerator at home in Côte d'Ivoire.

  International journal of STD & AIDS 20061101

• Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents.

  The Pediatric infectious disease journal 20061101

• Acid suppressive therapy and the effects on protease inhibitors.

  The Annals of pharmacotherapy 20061101

• Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20061101

• Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

  PLoS medicine 20061101

• Does HIV cause cardiovascular disease?

  PLoS medicine 20061101

• Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.

  AIDS patient care and STDs 20061101

• Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.

  AIDS research and human retroviruses 20061101

• XVI International AIDS Conference: Part 2.

  The AIDS reader 20061101

• Report from the XVI International AIDS Conference. Lopinavir/ritonavir monotherapy.

  AIDS clinical care 20061101

• Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.

  AIDS (London, England) 20061024

• Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction.

  Journal of chromatography. A 20061020

• Reduced lopinavir exposure during pregnancy.

  AIDS (London, England) 20061003

• Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.

  AIDS (London, England) 20061003

• Response to 'Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?' by Hill.

  AIDS (London, England) 20061003

• Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

  Bioorganic & medicinal chemistry 20061001

• Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

  Drug metabolism and disposition: the biological fate of chemicals 20061001

• A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

  Journal of acquired immune deficiency syndromes (1999) 20061001

• Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.

  The Annals of pharmacotherapy 20061001

• [Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].

  Enfermedades infecciosas y microbiologia clinica 20061001

• Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.

  Clinical pharmacology and therapeutics 20061001

• Viral and latent reservoir persistence in HIV-1-infected patients on therapy.

  PLoS computational biology 20061001

• TMC114 approved for resistant patients.

  AIDS patient care and STDs 20061001

• Abbott expands low cost Kaletra.

  AIDS patient care and STDs 20061001

• Evolution on distributive lattices.

  Journal of theoretical biology 20060921

• Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.

  Journal of the American Chemical Society 20060913

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.

  AIDS (London, England) 20060911

• Darunavir (Prezista) for HIV infection.

  The Medical letter on drugs and therapeutics 20060911

• Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.

  The Journal of pharmacology and experimental therapeutics 20060901

• Effectiveness of low-dose indinavir/ritonavir at 400/100 mg twice a day with 2 nucleoside reverse transcriptase inhibitors in nonnucleoside reverse transcriptase inhibitor-experienced HIV-infected patients in India: 1-year follow-up.

  Journal of acquired immune deficiency syndromes (1999) 20060901

• Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060901

• Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.

  The Journal of antimicrobial chemotherapy 20060901

• Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.

  The Journal of infectious diseases 20060901

• Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.

  The Journal of infectious diseases 20060901

• The urological management of the patient with acquired immunodeficiency syndrome.

  BJU international 20060901

• The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

  British journal of clinical pharmacology 20060901

• Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20060901

• Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient.

  Optometry (St. Louis, Mo.) 20060901

• Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

  Anti-cancer drugs 20060901

• Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.

  The Pediatric infectious disease journal 20060901

• SARS: systematic review of treatment effects.

  PLoS medicine 20060901

• [Medical care for HIV infection in France in 2005, the NADIS cohort study on 7416 patients].

  Medecine et maladies infectieuses 20060901

• Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20060824

• Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.

  AIDS (London, England) 20060822

• Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.

  JAMA 20060816

• Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.

  Lancet (London, England) 20060805

• The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

  Lancet (London, England) 20060805

• HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24.

  Leukemia research 20060801

• Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence.

  Journal of pharmacokinetics and pharmacodynamics 20060801

• Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.

  The Journal of antimicrobial chemotherapy 20060801

• Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

  British journal of clinical pharmacology 20060801

• Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines.

  Pharmacogenetics and genomics 20060801

• An update and review of antiretroviral therapy.

  Pharmacotherapy 20060801

• Hypokalemia in HIV patients on tenofovir.

  AIDS (London, England) 20060801

• Qualitative and quantitative analysis of pharmaceutical compounds by MALDI-TOF mass spectrometry.

  Analytical chemistry 20060801

• Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.

  Therapeutic drug monitoring 20060801

• Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.

  Clinical pharmacology and therapeutics 20060801

• New black box warning for ritonavir-boosted tipranavir.

  AIDS clinical care 20060801

• Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

  AIDS research and human retroviruses 20060801

• FDA clears HIV drug for patients with resistant virus.

  The AIDS reader 20060801

• Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20060713

• Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers.

  Biopharmaceutics & drug disposition 20060701

• Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model.

  American journal of obstetrics and gynecology 20060701

• Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.

  European journal of clinical pharmacology 20060701

• Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.

  Pediatric nephrology (Berlin, Germany) 20060701

• Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.

  Pharmaceutical research 20060701

• Time-dependent interaction between lopinavir/ritonavir and fexofenadine.

  Journal of clinical pharmacology 20060701

• Delirium in HIV-associated dementia.

  Journal of the American Academy of Child and Adolescent Psychiatry 20060701

• A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.

  PLoS clinical trials 20060701

• Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

  HIV medicine 20060701

• Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

  European journal of medical research 20060630

• Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.

  AIDS (London, England) 20060626

• Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

  Bioorganic & medicinal chemistry 20060615

• Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060615

• The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.

  Cancer chemotherapy and pharmacology 20060601

• Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.

  Antiviral research 20060601

• Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

  The Journal of antimicrobial chemotherapy 20060601

• Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects.

  The Journal of infectious diseases 20060601

• The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).

  Journal of acquired immune deficiency syndromes (1999) 20060601

• Antiretroviral drug resistance and routine therapy, Cameroon.

  Emerging infectious diseases 20060601

• Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

  The Annals of pharmacotherapy 20060601

• Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.

  Antimicrobial agents and chemotherapy 20060601

• FDA notifications. HIV-1 adult treatment guidelines are updated.

  AIDS alert 20060601

• Antiretroviral therapy 2006: pharmacology, applications, and special situations.

  Archives of pharmacal research 20060601

• Combining steroids with PIS.

  AIDS patient care and STDs 20060601

• HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism.

  Obesity (Silver Spring, Md.) 20060601

• Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

  AIDS (London, England) 20060512

• Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.

  AIDS (London, England) 20060512

• Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

  Biochemistry 20060502

• Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501

• Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy.

  The Journal of infectious diseases 20060501

• Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060501

• Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

  The Journal of general virology 20060501

• Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.

  Pharmacogenetics and genomics 20060501

• Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.

  Annals of neurology 20060501

• Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.

  Journal of clinical pharmacology 20060501

• Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20060501

• [Effects of various HIV protease inhibitors on function of rat insulinoma cells].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060501

• Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

  Clinical therapeutics 20060501

• Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

  AIDS (London, England) 20060424

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.

  AIDS (London, England) 20060424

• Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir.

  AIDS (London, England) 20060424

• Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.

  AIDS (London, England) 20060424

• Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060415

• Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.

  British journal of cancer 20060410

• Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.

  AIDS (London, England) 20060404

• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  Bioorganic & medicinal chemistry letters 20060401

• Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.

  HIV medicine 20060401

• Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort.

  British journal of clinical pharmacology 20060401

• Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.

  Therapeutic drug monitoring 20060401

• Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis.

  Journal of acquired immune deficiency syndromes (1999) 20060401

• Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.

  Journal of acquired immune deficiency syndromes (1999) 20060401

• Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5.

  Xenobiotica; the fate of foreign compounds in biological systems 20060401

• A review of nelfinavir for the treatment of HIV infection.

  Expert opinion on drug metabolism & toxicology 20060401

• [When Doctors Without Borders writes to Miles White, chairman of Abbott Laboratories].

  Revue medicale suisse 20060329

• MDR- and CYP3A4-mediated drug-herbal interactions.

  Life sciences 20060327

• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

  AIDS (London, England) 20060321

• Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

  AIDS (London, England) 20060321

• Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060320

• Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060315

• Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

  PLoS medicine 20060301

• Biosensor-based screening and characterization of HIV-1 inhibitor interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans.

  Journal of biomolecular screening 20060301

• Antiretroviral therapy and dyslipidaemia: unlocking the code.

  PLoS medicine 20060301

• Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

  HIV medicine 20060301

• Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

  HIV medicine 20060301

• Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.

  The Journal of antimicrobial chemotherapy 20060301

• Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.

  Journal of clinical pharmacology 20060301

• Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

  The Annals of pharmacotherapy 20060301

• Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir.

  Clinical pharmacology and therapeutics 20060301

• Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20060301

• Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?

  Journal of acquired immune deficiency syndromes (1999) 20060301

• Effects of the ritonavir price increase on the cost of protease inhibitor regimens in United States.

  Managed care interface 20060301

• Ritonavir and fluticasone: beware of this potentially fatal combination.

  The Journal of pediatrics 20060301

• Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone.

  The Journal of pediatrics 20060301

• API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.

  The Journal of the Association of Physicians of India 20060301

• Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.

  The Journal of infection 20060201

• HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.

  Cell death and differentiation 20060201

• Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.

  Therapeutic drug monitoring 20060201

• Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.

  Journal of clinical pharmacology 20060201

• JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis.

  Journal of hepato-biliary-pancreatic surgery 20060201

• Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

  AIDS research and human retroviruses 20060201

• Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.

  Current opinion in investigational drugs (London, England : 2000) 20060201

• [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].

  Revista clinica espanola 20060201

• Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.

  The Journal of biological chemistry 20060120

• Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.

  Blood 20060115

• Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060115

• Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.

  AIDS (London, England) 20060109

• Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core.

  Organic letters 20060105

• Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.

  AIDS (London, England) 20060102

• High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

  AIDS (London, England) 20060102

• Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study.

  AIDS (London, England) 20060102

• Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.

  Biomedical chromatography : BMC 20060101

• HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.

  The Journal of pharmacology and experimental therapeutics 20060101

• Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue.

  Arteriosclerosis, thrombosis, and vascular biology 20060101

• Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.

  Archives of medical research 20060101

• HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.

  Metabolism: clinical and experimental 20060101

• Bleomycin has antiviral properties against drug-resistant HIV strains and sensitises virus to currently used antiviral agents.

  International journal of antimicrobial agents 20060101

• Update on HAART in HIV.

  Journal of hepatology 20060101

• Antiviral hepatitis and antiretroviral drug interactions.

  Journal of hepatology 20060101

• Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.

  The Annals of pharmacotherapy 20060101

• The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

  Cerebrospinal fluid research 20060101

• Pharmacoenhancement of protease inhibitors.

  American journal of therapeutics 20060101

• Case study: an active, 24-year-old woman positive for HIV.

  JAAPA : official journal of the American Academy of Physician Assistants 20060101

• Saquinavir/Ritonavir: its evolution and current treatment role.

  The AIDS reader 20060101

• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  Basic & clinical pharmacology & toxicology 20060101

• Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy.

  BMC infectious diseases 20060101

• Genotypic and phenotypic analyses of human immunodeficiency virus type 1 in antiretroviral drug-naive Nigerian patients.

  AIDS research and human retroviruses 20060101

• [HIV infection presenting with bilateral optic neuropathy].

  Revue neurologique 20060101

• [Antiretroviral drugs in severe acute respiratory syndrome].

  Presse medicale (Paris, France : 1983) 20060101

• Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

  Clinical pharmacokinetics 20060101

• [Tipranavir (used with ritonavir)].

  Revue de l'infirmiere 20060101

• Understanding and avoiding antiretroviral adverse events.

  Current pharmaceutical design 20060101

• Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.

  Antiviral therapy 20060101

• Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

  Antiviral therapy 20060101

• Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma.

  Clinical chemistry and laboratory medicine 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.

  Journal of pharmacological and toxicological methods 20060101

• Antiretroviral treatment of HIV infection: Swedish recommendations 2005.

  Scandinavian journal of infectious diseases 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART.

  Postepy higieny i medycyny doswiadczalnej (Online) 20060101

• Tipranavir: PNU 140690, tipranivir.

  Drugs in R&D 20060101

• Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations.

  HIV clinical trials 20060101

• Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.

  Antiviral therapy 20060101

• Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

  Antiviral therapy 20060101

• Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

  Antiviral therapy 20060101

• Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.

  Cell biochemistry and biophysics 20060101

• Subclinical hypothyroidism in HIV-infected patients is not an autoimmune disease.

  Hormone research 20060101

• [Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir].

  Revista espanola de medicina nuclear 20060101

• Tipranavir: a protease inhibitor for HIV salvage therapy.

  The Annals of pharmacotherapy 20060101

• A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.

  Rapid communications in mass spectrometry : RCM 20060101

• Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy.

  HIV clinical trials 20060101

• Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.

  HIV clinical trials 20060101

• Tipranavir: a novel nonpeptidic protease inhibitor of HIV.

  Clinical pharmacokinetics 20060101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20060101

• Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

  BMC infectious diseases 20060101

• New protease inhibitor offers clinicians hope for better salvage therapy.

  HIV clinician 20060101

• Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).

  Antiviral therapy 20060101

• Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

  Antiviral therapy 20060101

• Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

  Antiviral therapy 20060101

• Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.

  Radiation oncology (London, England) 20060101

• Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.

  MedGenMed : Medscape general medicine 20060101

• The pathogenesis of HIV infection: stupid may not be so dumb after all.

  Retrovirology 20060101

• Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.

  Antiviral therapy 20060101

• Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.

  Antiviral therapy 20060101

• Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.

  Antiviral therapy 20060101

• Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.

  Antiviral therapy 20060101

• Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.

  BMC infectious diseases 20060101

• Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.

  Journal of chemical information and modeling 20060101

• Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

  HIV clinical trials 20060101

• [Methadone: from pharmacokinetic profile to clinical pharmacology].

  L'Encephale 20060101

• Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.

  Drugs 20060101

• An immunological comparison of third companion in advanced drug-naive HIV-infected patients.

  HIV clinical trials 20060101

• A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.

  HIV clinical trials 20060101

• Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

  Clinical drug investigation 20060101

• Drug-herb interactions: eliminating toxicity with hard drug design.

  Current pharmaceutical design 20060101

• Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.

  The Journal of eukaryotic microbiology 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

  PloS one 20060101

• Choroid plexus epithelial monolayers--a cell culture model from porcine brain.

  Cerebrospinal fluid research 20060101

• Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand.

  Cost effectiveness and resource allocation : C/E 20060101

• Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.

  HIV clinical trials 20060101

• Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.

  HIV clinical trials 20060101

• Anti-HIV agents. Some drug interactions with Merck's integrase inhibitor.

  TreatmentUpdate 20060101

• Anti-HIV agents. Darunavir shows its strength.

  TreatmentUpdate 20060101

• Drug interactions. Is atazanavir best when boosted with ritonavir?

  TreatmentUpdate 20060101

• Drug interactions. Unexpected interaction between T-20 and some protease inhibitors.

  TreatmentUpdate 20060101

• Drug interactions. Coming soon--a new formulation of Kaletra.

  TreatmentUpdate 20060101

• Drug interactions. Kaletra and ezetimibe.

  TreatmentUpdate 20060101

• Drug interactions. Kaletra and atazanavir.

  TreatmentUpdate 20060101

• Drug interactions. Amprenavir with low-dose ritonavir.

  TreatmentUpdate 20060101

• [Development and validation of laboratory methods for antiretroviral quantitation using HPLC].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101

• Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).

  Antiviral therapy 20060101

• Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.

  Antiviral therapy 20060101

• New HIV treatment.

  FDA consumer 20060101

• Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors.

  Bioinorganic chemistry and applications 20060101

• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

  Journal of the International AIDS Society 20060101

• Activists lift boycott of Abbott Laboratories.

  AIDS policy & law 20051230

• Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227

• Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

  Bioorganic & medicinal chemistry letters 20051215

• Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20051215

• Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Adherence to antiretroviral therapy: merging the clinical and social course of AIDS.

  PLoS medicine 20051201

• Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

  The Journal of antimicrobial chemotherapy 20051201

• Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.

  Journal of medical virology 20051201

• Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.

  Journal of acquired immune deficiency syndromes (1999) 20051201

• No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.

  Therapeutic drug monitoring 20051201

• In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin.

  The FEBS journal 20051201

• Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.

  Clinical pharmacology and therapeutics 20051201

• Tipranavir.

  Nature reviews. Drug discovery 20051201

• Ritonavir and lopinavir/ritonavir package inserts are updated.

  AIDS alert 20051201

• [Protease inhibitors].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20051201

• Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

  Therapeutics and clinical risk management 20051201

• Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.

  AIDS (London, England) 20051118

• Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

  AIDS (London, England) 20051118

• Drug pricing. Dismissal is denied in Norvir price-boosting suit.

  AIDS policy & law 20051118

• Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study.

  AIDS (London, England) 20051104

• Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.

  AIDS (London, England) 20051104

• In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.

  The Journal of antimicrobial chemotherapy 20051101

• Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051101

• Immunodysregulation of HIV disease at bone marrow level.

  Autoimmunity reviews 20051101

• Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

  HIV medicine 20051101

• The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.

  HIV medicine 20051101

• Antiretroviral treatment in the Northern Cape.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20051101

• FDA notifications. FDA approves pediatric dosing for ritonavir.

  AIDS alert 20051101

• Tipranavir.

  Drugs of today (Barcelona, Spain : 1998) 20051101

• Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051015

• Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

  The Journal of infectious diseases 20051015

• MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.

  AIDS (London, England) 20051014

• Determination of antiretroviral agents in human serum by capillary electrophoresis.

  Journal of chromatography. A 20051014

• Tipranavir (Aptivus) for HIV.

  The Medical letter on drugs and therapeutics 20051010

• Torcetrapib and atorvastatin.

  The New England journal of medicine 20051006

• Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20051001

• In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.

  Anti-cancer drugs 20051001

• Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.

  British journal of clinical pharmacology 20051001

• Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

  The Pediatric infectious disease journal 20051001

• Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

  The Pediatric infectious disease journal 20051001

• Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

  The Pediatric infectious disease journal 20051001

• PI monotherapy effective as maintenance.

  AIDS patient care and STDs 20051001

• Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

  Current medical research and opinion 20051001

• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  Current drug metabolism 20051001

• Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.

  The AIDS reader 20051001

• Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.

  The AIDS reader 20051001

• Meeting notes from the 3rd IAS Conference. Old drugs, new data.

  AIDS clinical care 20051001

• The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20051001

• Focus on hepatitis. Low rate of liver problems seen with LPV/r.

  IAPAC monthly 20051001

• Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region.

  Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research 20051001

• HIV protease inhibitor ritonavir increases endothelial monolayer permeability.

  Biochemical and biophysical research communications 20050930

• Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS.

  AIDS (London, England) 20050923

• Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.

  Bioorganic & medicinal chemistry letters 20050915

• HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

  Cancer research 20050915

• The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.

  AIDS (London, England) 20050902

• Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.

  AIDS (London, England) 20050902

• HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.

  Molecular pharmacology 20050901

• Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20050901

• Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

  British journal of clinical pharmacology 20050901

• Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

  British journal of clinical pharmacology 20050901

• Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.

  The Pediatric infectious disease journal 20050901

• The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

  Dialogues in clinical neuroscience 20050901

• The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

  HIV medicine 20050901

• Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids.

  The AIDS reader 20050901

• Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050815

• Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

  The Journal of antimicrobial chemotherapy 20050801

• Anti-viral activity of human antithrombin III.

  International journal of molecular medicine 20050801

• Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050801

• Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.

  Clinical pharmacology and therapeutics 20050801

• Review of atazanavir: a novel HIV protease inhibitor.

  Expert opinion on pharmacotherapy 20050801

• Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.

  Expert opinion on pharmacotherapy 20050801

• Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis.

  Chemotherapy 20050801

• Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.

  AIDS research and human retroviruses 20050801

• Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.

  British journal of cancer 20050725

• Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines.

  AIDS (London, England) 20050722

• Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases.

  The Journal of clinical endocrinology and metabolism 20050701

• Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

  International journal of antimicrobial agents 20050701

• Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

  The Journal of antimicrobial chemotherapy 20050701

• Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

  The Journal of clinical investigation 20050701

• Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.

  AIDS (London, England) 20050701

• Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.

  AIDS (London, England) 20050701

• Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.

  British journal of clinical pharmacology 20050701

• Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.

  Biological & pharmaceutical bulletin 20050701

• Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.

  The Journal of infectious diseases 20050615

• A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050615

• TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.

  AIDS (London, England) 20050610

• [New antiretroviral treatment modalities].

  Presse medicale (Paris, France : 1983) 20050604

• [Treatment of the human immunodeficiency virus in adults in 2005].

  Presse medicale (Paris, France : 1983) 20050604

• Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries.

  American journal of physiology. Heart and circulatory physiology 20050601

• Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

  The Journal of clinical endocrinology and metabolism 20050601

• Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

  The Journal of antimicrobial chemotherapy 20050601

• Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.

  The Journal of antimicrobial chemotherapy 20050601

• Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers.

  European journal of clinical pharmacology 20050601

• Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression.

  Journal of acquired immune deficiency syndromes (1999) 20050601

• Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

  Therapeutic drug monitoring 20050601

• Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.

  Fundamental & clinical pharmacology 20050601

• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

  Antimicrobial agents and chemotherapy 20050601

• Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.

  Antimicrobial agents and chemotherapy 20050601

• Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries.

  Journal of the American College of Surgeons 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• More PI drug interactions.

  AIDS patient care and STDs 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors.

  Acta paediatrica (Oslo, Norway : 1992) 20050601

• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525

• Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

  AIDS (London, England) 20050520

• Oximinoarylsulfonamides as potent HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050502

• Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

  The Journal of antimicrobial chemotherapy 20050501

• Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.

  The Journal of infectious diseases 20050501

• Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

  Journal of acquired immune deficiency syndromes (1999) 20050501

• Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.

  Journal of the American Academy of Dermatology 20050501

• Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.

  AIDS research and human retroviruses 20050501

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• Is ritonavir boosting associated with gout?

  International journal of STD & AIDS 20050501

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050429

• Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone.

  AIDS (London, England) 20050429

• CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol.

  Free radical biology & medicine 20050415

• Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050415

• Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050415

• Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

  The Journal of antimicrobial chemotherapy 20050401

• Lopinavir/ritonavir combination and total/HDL cholesterol ratio.

  The Journal of infection 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

  British journal of clinical pharmacology 20050401

• The effect of treatment with a protease inhibitor on mycobacterial infection.

  Diagnostic microbiology and infectious disease 20050401

• [Meningeal cryptococcosis as a sign of immune reconstitution syndrome].

  Enfermedades infecciosas y microbiologia clinica 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• FDA notifications. BMS issues letter about omeprazole.

  AIDS alert 20050401

• Roche issues drug interaction warning.

  AIDS alert 20050401

• Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.

  AIDS (London, England) 20050325

• Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

  Journal of medicinal chemistry 20050324

• Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.

  AIDS (London, England) 20050304

• Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

  HIV medicine 20050301

• Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.

  HIV medicine 20050301

• Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

  Therapeutics and clinical risk management 20050301

• Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

  AIDS (London, England) 20050218

• Ritonavir does not inhibit calpain in vitro.

  Biochemical and biophysical research communications 20050204

• Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

  The Journal of pharmacology and experimental therapeutics 20050201

• Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

  Pediatrics 20050201

• Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.

  Journal of clinical pharmacology 20050201

• The pharmacokinetics of HIV protease inhibitor combinations.

  Current opinion in infectious diseases 20050201

• Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.

  The Journal of antimicrobial chemotherapy 20050201

• Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.

  European journal of clinical pharmacology 20050201

• Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.

  Journal of acquired immune deficiency syndromes (1999) 20050201

• Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.

  British journal of clinical pharmacology 20050201

• Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use.

  AIDS patient care and STDs 20050201

• Blockade of HERG channels by HIV protease inhibitors.

  Lancet (London, England) 20050201

• Pill burden reduced for saquinavir.

  AIDS patient care and STDs 20050201

• Tipranavir: a novel second-generation nonpeptidic protease inhibitor.

  Expert review of anti-infective therapy 20050201

• Development of hepatotoxicity in HIV patients switching at least one protease inhibitor.

  International journal of STD & AIDS 20050201

• The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

  Current HIV/AIDS reports 20050201

• Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

  AIDS (London, England) 20050128

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050128

• Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection.

  AIDS (London, England) 20050128

• Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.

  European journal of medical research 20050128

• Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines.

  The Journal of biological chemistry 20050121

• Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050115

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

  British journal of clinical pharmacology 20050101

• Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).

  Journal of acquired immune deficiency syndromes (1999) 20050101

• Acquired macroglossia due to lopinavir/ritonavir treatment.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20050101

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats.

  Biological & pharmaceutical bulletin 20050101

• Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

  BMC infectious diseases 20050101

• Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide.

  Clinical pharmacokinetics 20050101

• No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.

  Annals of clinical microbiology and antimicrobials 20050101

• HIV type 1 protease inhibitors enhance bone marrow progenitor cell activity in normal subjects and in HIV type 1-infected patients.

  AIDS research and human retroviruses 20050101

• Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction.

  Internal medicine journal 20050101

• Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.

  HIV medicine 20050101

• Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.

  International journal of immunopathology and pharmacology 20050101

• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

  Lipids in health and disease 20050101

• Molecular strategies to inhibit HIV-1 replication.

  Retrovirology 20050101

• Top stories of 2004. Back to the future: lopinavir/ritonavir as 'monotherapy'.

  AIDS clinical care 20050101

• Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.

  AIDS clinical care 20050101

• Drug bioactivation, covalent binding to target proteins and toxicity relevance.

  Drug metabolism reviews 20050101

• Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

  Drugs 20050101

• Maculo-papular rash induced by lopinavir/ritonavir.

  European journal of dermatology : EJD 20050101

• Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

  Clinical pharmacokinetics 20050101

• Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers.

  Journal of biochemical and molecular toxicology 20050101

• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20050101

• Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.

  Antiviral therapy 20050101

• The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

  Antiviral therapy 20050101

• The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life.

  Health and quality of life outcomes 20050101

• Herb-drug interactions: a literature review.

  Drugs 20050101

• Identifying the stable polymorph early in the drug discovery-development process.

  Pharmaceutical development and technology 20050101

• High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus.

  BMC infectious diseases 20050101

• [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].

  Therapie 20050101

• Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

  HIV clinical trials 20050101

• Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.

  HIV clinical trials 20050101

• Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

  HIV clinical trials 20050101

• Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

  BMC infectious diseases 20050101

• Tipranavir: a ritonavir-boosted protease inhibitor.

  Drugs 20050101

• Tandem machine learning for the identification of genes regulated by transcription factors.

  BMC bioinformatics 20050101

• Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

  Antiviral therapy 20050101

• The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.

  Antiviral therapy 20050101

• Anthracyclines, proteasome activity and multi-drug-resistance.

  BMC cancer 20050101

• Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

  Clinical pharmacokinetics 20050101

• Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• Aptivus in the hotseat. Excerpts from the FDA hearings.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20050101

• ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

  Cancer cell international 20050101

• A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

  Antiviral therapy 20050101

• A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.

  Antiviral therapy 20050101

• Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

  BMC infectious diseases 20050101

• Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop.

  AIDS reviews 20050101

• Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20050101

• Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.

  Anticancer research 20050101

• Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.

  Antiviral therapy 20050101

• Scutellaria baicalensis decreases ritonavir-induced nausea.

  AIDS research and therapy 20050101

• High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

  Clinical pharmacokinetics 20050101

• [Treatment of chronic hepatitis C in patients with HIV infection].

  Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 20050101

• Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

  International journal of immunopathology and pharmacology 20050101

• New therapy for advanced HIV.

  FDA consumer 20050101

• Predictors of virologic response to ritonavir-boosted protease inhibitors.

  AIDS reviews 20050101

• Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.

  Antiviral therapy 20050101

• Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy.

  Antiviral therapy 20050101

• [New formulation--fewer tablets--optimal effect].

  Krankenpflege Journal 20050101

• Anti-HIV agents. Tipranavir in treatment-experienced PHAs.

  TreatmentUpdate 20050101

• Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.

  Journal of the International AIDS Society 20050101

• Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.

  Core evidence 20050101

• Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.

  Bioorganic & medicinal chemistry letters 20041206

• The HIV protease inhibitor ritonavir synergizes with butyrate for induction of apoptotic cell death and mediates expression of heme oxygenase-1 in DLD-1 colon carcinoma cells.

  British journal of pharmacology 20041201

• Antiretrovirals as antimalarial agents.

  The Journal of infectious diseases 20041201

• Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20041201

• Atazanavir for the treatment of human immunodeficiency virus infection.

  Pharmacotherapy 20041201

• Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

  The Journal of endocrinology 20041201

• An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.

  Journal of immunological methods 20041201

• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

  Antiviral therapy 20041201

• Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.

  Antiviral therapy 20041201

• The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin.

  Antiviral therapy 20041201

• Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg.

  Antiviral therapy 20041201

• Determination of saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography and the analytical error function.

  Journal of pharmaceutical and biomedical analysis 20041119

• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

  AIDS (London, England) 20041119

• First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.

  AIDS (London, England) 20041119

• Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.

  Journal of medicinal chemistry 20041118

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

  AIDS (London, England) 20041105

• Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance.

  Drug metabolism and disposition: the biological fate of chemicals 20041101

• Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101

• Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.

  The Journal of antimicrobial chemotherapy 20041101

• Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20041101

• Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20041101

• Atazanavir: A novel once-daily protease inhibitor.

  Drugs of today (Barcelona, Spain : 1998) 20041101

• Pharmacokinetics of Telzir (fosamprenavir).

  Journal of HIV therapy 20041101

• [Therapeutic strategies for HIV infection: clinical approach with boost antiproteases in adults].

  Medecine et maladies infectieuses 20041101

• [Therapeutic strategies for HIV infection: tolerance to boost antiproteases].

  Medecine et maladies infectieuses 20041101

• Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015

• HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

  Cancer research 20041015

• A 4'-C-ethynyl-2',3'-dideoxynucleoside analogue highlights the role of the 3'-OH in anti-HIV active 4'-C-ethynyl-2'-deoxy nucleosides.

  Journal of medicinal chemistry 20041007

• Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.

  The Journal of antimicrobial chemotherapy 20041001

• Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20041001

• Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.

  Therapeutic drug monitoring 20041001

• Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.

  Therapeutic drug monitoring 20041001

• Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

  Antimicrobial agents and chemotherapy 20041001

• Efavirenz for HIV-1 infection in adults: an overview.

  Expert review of anti-infective therapy 20041001

• The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.

  Antiviral therapy 20041001

• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  Current drug metabolism 20041001

• Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.

  Pharmaceutical research 20041001

• Antiretroviral protease inhibitors prevent l6 muscle cell fusion by reducing calpain activity.

  AIDS research and human retroviruses 20041001

• Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20041001

• Hepatitis coinfection and LPV/RTV.

  IAPAC monthly 20041001

• Binding of anti-HIV drugs to human serum albumin.

  IUBMB life 20041001

• HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.

  IUBMB life 20041001

• Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.

  Biochemistry 20040928

• Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.

  AIDS (London, England) 20040924

• Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.

  The international journal of biochemistry & cell biology 20040901

• Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.

  Journal of medical virology 20040901

• Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20040901

• Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20040901

• Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

  HIV medicine 20040901

• Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.

  HIV medicine 20040901

• Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.

  Pharmaceutical research 20040901

• Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.

  Pharmaceutical research 20040901

• Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.

  Journal of acquired immune deficiency syndromes (1999) 20040815

• Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations.

  Journal of acquired immune deficiency syndromes (1999) 20040815

• A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815

• Patents. NIH declines to march in on pricing AIDS drug.

  Science (New York, N.Y.) 20040813

• The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors.

  Journal of medical virology 20040801

• Advancements in the battle against severe acute respiratory syndrome.

  Expert opinion on pharmacotherapy 20040801

• Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801

• Resistance to HIV protease inhibitors: mechanisms and clinical consequences.

  Current drug metabolism 20040801

• Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

  American journal of obstetrics and gynecology 20040801

• The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

  Antiviral therapy 20040801

• Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

  Antiviral therapy 20040801

• Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

  Antiviral therapy 20040801

• Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

  Prescrire international 20040801

• Practical considerations for the clinical use of buprenorphine.

  Science & practice perspectives 20040801

• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

  AIDS (London, England) 20040723

• ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells.

  Blood 20040715

• Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

  The Journal of infectious diseases 20040715

• The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

  The Journal of clinical investigation 20040715

• Advertisements. FDA orders Abbott to change misleading ads for Norvir.

  AIDS policy & law 20040702

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries.

  Cardiovascular research 20040701

• Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

  Journal of clinical pharmacology 20040701

• Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.

  Drug metabolism and disposition: the biological fate of chemicals 20040701

• Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers.

  Clinical pharmacology and therapeutics 20040701

• Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.

  HIV medicine 20040701

• A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.

  HIV medicine 20040701

• Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20040701

• PENTA guidelines for the use of antiretroviral therapy, 2004.

  HIV medicine 20040701

• Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

  AIDS (London, England) 20040618

• High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.

  Biochemical and biophysical research communications 20040604

• Intellectual property. NIH weighs demand to force sharing of AIDS drug patents.

  Science (New York, N.Y.) 20040604

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• Atazanavir: new option for treatment of HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040601

• Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.

  Therapeutic drug monitoring 20040601

• Direct interference of HIV protease inhibitors with pancreatic beta-cell function.

  Naunyn-Schmiedeberg's archives of pharmacology 20040601

• Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

  Pharmacotherapy 20040601

• Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events.

  International journal of impotence research 20040601

• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

  Antiviral therapy 20040601

• Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

  Antiviral therapy 20040601

• [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

  Parassitologia 20040601

• RTV patent under fire.

  IAPAC monthly 20040601

• Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs.

  Bioorganic & medicinal chemistry 20040515

• [New treatment options for HIV-infected patients].

  Deutsche medizinische Wochenschrift (1946) 20040507

• Drug pricing. HIV/AIDS patients file federal antitrust suit against Abbott.

  AIDS policy & law 20040507

• AIDS drug price hike prompts calls for intervention.

  Nature 20040506

• HIV protease inhibitors increase adiponectin levels in HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20040501

• Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.

  Pharmacotherapy 20040501

• Can we boost enough without ritonavir?

  The AIDS reader 20040501

• Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient.

  AIDS (London, England) 20040430

• [From HAART to 'smart': maximizing the advantages of lopinavir/ritonavir].

  MMW Fortschritte der Medizin 20040426

• [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].

  MMW Fortschritte der Medizin 20040426

• [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].

  MMW Fortschritte der Medizin 20040426

• [FPV plus SQV plus a mini-dose ritonavir. 'Double boosting with compatible partners].

  MMW Fortschritte der Medizin 20040426

• Drug company raises US price of AIDS drug five-fold.

  BMJ (Clinical research ed.) 20040424

• Debate over ritonavir price increase gains momentum. Critics seek to reverse the fivefold price hike through legal action and boycott of Abbott's products.

  Lancet (London, England) 20040424

• Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040415

• Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.

  AIDS (London, England) 20040409

• Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection.

  AIDS (London, England) 20040409

• A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.

  Journal of medicinal chemistry 20040408

• Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20040401

• Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.

  Antiviral research 20040401

• Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

  The Journal of infectious diseases 20040401

• Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040401

• Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040401

• Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.

  Infection 20040401

• Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

  Clinical pharmacology and therapeutics 20040401

• Integrating in vitro kinetic data from compounds exhibiting induction, reversible inhibition and mechanism-based inactivation: in vitro study design.

  Current drug metabolism 20040401

• HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.

  Molecular cancer therapeutics 20040401

• Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20040401

• Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

  Pharmacotherapy 20040401

• Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).

  Antiviral therapy 20040401

• Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy.

  Antiviral therapy 20040401

• Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).

  Antiviral therapy 20040401

• Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

  Antiviral therapy 20040401

• IQ predicts treatment response.

  AIDS patient care and STDs 20040401

• Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

  AIDS (London, England) 20040326

• The longer the better? Four years of durable, initially boosted protease treatment.

  AIDS (London, England) 20040326

• Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

  The Journal of infectious diseases 20040315

• The metabolic effects of lopinavir/ritonavir in HIV-negative men.

  AIDS (London, England) 20040305

• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

  AIDS (London, England) 20040305

• Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases.

  AIDS (London, England) 20040305

• The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig.

  The Journal of pharmacology and experimental therapeutics 20040301

• Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.

  Journal of pharmaceutical sciences 20040301

• Anticonvulsant and antiretroviral interactions.

  The Annals of pharmacotherapy 20040301

• The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.

  Journal of clinical pharmacology 20040301

• Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

  Drug metabolism and disposition: the biological fate of chemicals 20040301

• Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

  Thorax 20040301

• Drug-induced liver injury.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Liver toxicity in epidemiological cohorts.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040301

• Combo approved for HIV treatment.

  The Nurse practitioner 20040301

• In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.

  Pharmaceutical research 20040301

• Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20040301

• Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.

  Journal of acquired immune deficiency syndromes (1999) 20040301

• Abbott announces RTV price concessions.

  IAPAC monthly 20040301

• Boosted saquinavir approved.

  AIDS patient care and STDs 20040301

• Changes in Kaletra labelling.

  AIDS patient care and STDs 20040301

• Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.

  AIDS research and human retroviruses 20040301

• Simultaneous determination of indinavir, ritonavir and saquinavir in plasma by high-performance liquid chromatography.

  Journal of the Formosan Medical Association = Taiwan yi zhi 20040301

• Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.

  International journal of antimicrobial agents 20040301

• Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART.

  Antiviral research 20040301

• Drug pricing. AHF presses for indemnification over Norvir price increase.

  AIDS policy & law 20040227

• Drug pricing. AHF sues Abbott over drug price increase.

  AIDS policy & law 20040227

• Phase transformation considerations during process development and manufacture of solid oral dosage forms.

  Advanced drug delivery reviews 20040223

• Ritonavir exhibits anti-atherogenic properties on vascular smooth muscle cells.

  AIDS (London, England) 20040220

• Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

  AIDS (London, England) 20040220

• Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients.

  AIDS (London, England) 20040220

• The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma.

  International journal of cancer 20040210

• Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.

  Endocrinology 20040201

• Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040201

• Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.

  Antimicrobial agents and chemotherapy 20040201

• Lopinavir protein binding in vivo through the 12-hour dosing interval.

  Therapeutic drug monitoring 20040201

• [Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen].

  Enfermedades infecciosas y microbiologia clinica 20040201

• Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers.

  Biological & pharmaceutical bulletin 20040201

• SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.

  Hepatology (Baltimore, Md.) 20040201

• Call to rescind price boosting of ritonavir.

  The Lancet. Infectious diseases 20040201

• Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.

  Xenobiotica; the fate of foreign compounds in biological systems 20040201

• Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo.

  Molecular cancer therapeutics 20040201

• Controversy over ritonavir price increase.

  AIDS clinical care 20040201

• Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

  Antiviral therapy 20040201

• Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

  Antiviral therapy 20040201

• Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.

  Antiviral therapy 20040201

• Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.

  Antiviral therapy 20040201

• Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.

  AIDS (London, England) 20040123

• Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

  The Journal of infectious diseases 20040115

• Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay.

  Journal of theoretical biology 20040107

• Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20040102

• Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.

  AIDS (London, England) 20040102

• Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20040101

• Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20040101

• Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

  The Journal of infectious diseases 20040101

• The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).

  HIV medicine 20040101

• A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.

  HIV medicine 20040101

• Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals.

  The new microbiologica 20040101

• A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.

  American journal of therapeutics 20040101

• A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102).

  HIV clinical trials 20040101

• Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

  AIDS patient care and STDs 20040101

• Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.

  Journal of molecular recognition : JMR 20040101

• Ritonavir increases levels of erectile dysfunction agent 49 fold.

  HIV clinician 20040101

• Pharmacokinetic enhancement of protease inhibitor therapy.

  Clinical pharmacokinetics 20040101

• Norvir hangover.

  Positively aware : the monthly journal of the Test Positive Aware Network 20040101

• 400 percent ritonavir price hike.

  IAPAC monthly 20040101

• Doctors organize to protest Abbott's Norvir price hike.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Abbott Laboratories' pricing malfunction.

  Survival news (Atlanta, Ga.) 20040101

• Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites.

  Journal of medical Internet research 20040101

• In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.

  American journal of therapeutics 20040101

• Recurrent oedema associated with the co-formulation of lopinavir and ritonavir.

  Revista da Sociedade Brasileira de Medicina Tropical 20040101

• Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection.

  Drugs 20040101

• Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.

  Clinical pharmacokinetics 20040101

• Abbott's Norvir price hike is bad medicine. Statement at the NIH public meeting on Norvir.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101

• FDA issues warning letter to Abbott over Norvir pricing spin.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101

• Remission of HIV-associated myelopathy after highly active antiretroviral therapy.

  Journal of postgraduate medicine 20040101

• Backlash over ritonavir price hike.

  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20040101

• Predictors of virological response to atazanavir in protease inhibitor-experienced patients.

  HIV clinical trials 20040101

• Effect of chronic ritonavir administration on pregnant rats and their fetuses.

  Clinical and experimental obstetrics & gynecology 20040101

• Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

  Clinical pharmacokinetics 20040101

• Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy.

  BMC infectious diseases 20040101

• Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes).

  Theoretical biology & medical modelling 20040101

• Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3.

  Retrovirology 20040101

• Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

  HIV clinical trials 20040101

• Pharmacokinetics of antiretrovirals in pregnant women.

  Clinical pharmacokinetics 20040101

• Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

  HIV clinical trials 20040101

• Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).

  HIV clinical trials 20040101

• Considerations in selecting protease inhibitor therapy.

  AIDS reviews 20040101

• Protease-inhibitor boosting in the treatment-experienced patient.

  AIDS reviews 20040101

• Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

  Scandinavian journal of infectious diseases 20040101

• Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• The demise of Bayh-Dole protections against the Pharmaceutical Industry's abuses of government-funded inventions.

  The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 20040101

• Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.

  Molecular pharmaceutics 20040101

• Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.

  Biochemistry 20031230

• Abbott Laboratories increases Norvir price fivefold.

  AIDS treatment news 20031226

• Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031215

• Treatment of antiretroviral-drug-resistant HIV-1 infection.

  Lancet (London, England) 20031213

• [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].

  MMW Fortschritte der Medizin 20031211

• Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.

  AIDS (London, England) 20031205

• Tacrolimus and lopinavir/ritonavir interaction in liver transplantation.

  The Annals of pharmacotherapy 20031201

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031201

• Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir.

  International journal of antimicrobial agents 20031201

• Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

  Hong Kong medical journal = Xianggang yi xue za zhi 20031201

• P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.

  Addiction biology 20031201

• HIV protease inhibitor ritonavir induces lipoatrophy in male mice.

  AIDS research and human retroviruses 20031201

• Package insert revisions for ritonavir.

  AIDS patient care and STDs 20031201

• A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20031201

• Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.

  Antiviral therapy 20031201

• Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

  Dermatology online journal 20031201

• Open letter from ATAC to Abbott's CEO, Miles White.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20031201

• HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.

  The Journal of biological chemistry 20031128

• Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.

  Biochemistry 20031125

• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.

  British journal of cancer 20031117

• Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir.

  AIDS (London, England) 20031107

• Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands.

  Bioorganic & medicinal chemistry letters 20031103

• Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases.

  Bioorganic & medicinal chemistry 20031103

• Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.

  Expert opinion on investigational drugs 20031101

• Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.

  Biopharmaceutics & drug disposition 20031101

• MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.

  Journal of acquired immune deficiency syndromes (1999) 20031101

• Treating advanced HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20031101

• The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study.

  International journal of STD & AIDS 20031101

• Risk factors for lipodystrophy in the CISAI cohort.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20031101

• Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry.

  Antiviral chemistry & chemotherapy 20031101

• SARS: pharmacotherapy.

  Respirology (Carlton, Vic.) 20031101

• [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].

  Medicina clinica 20031025

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.

  AIDS (London, England) 20031017

• Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain.

  Biochemical pharmacology 20031015

• [Interaction between methadone and antiretrovirals (stavudine, indinavir, ritonavir, nevirapine)].

  Medicina clinica 20031004

• Modulation of the LDL receptor and LRP levels by HIV protease inhibitors.

  Journal of lipid research 20031001

• Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20031001

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031001

• Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.

  HIV medicine 20031001

• Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells.

  HIV medicine 20031001

• Fatal lactic acidosis during antiretroviral therapy.

  Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 20031001

• Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.

  Journal of acquired immune deficiency syndromes (1999) 20031001

• Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.

  Current drug metabolism 20031001

• Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting.

  AIDS research and human retroviruses 20031001

• More data released on 908.

  AIDS patient care and STDs 20031001

• A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).

  Antiviral therapy 20031001

• HCV snapshots: macro to micro.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20031001

• Atazanavir (Reyataz).

  Project Inform perspective 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.

  AIDS (London, England) 20030905

• Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.

  The Journal of antimicrobial chemotherapy 20030901

• Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

  The Journal of antimicrobial chemotherapy 20030901

• Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative.

  Drug metabolism and disposition: the biological fate of chemicals 20030901

• Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.

  The Annals of pharmacotherapy 20030901

• Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

  The Journal of infectious diseases 20030901

• In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

  Antimicrobial agents and chemotherapy 20030901

• Irreversible coma, ergotamine, and ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901

• Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20030901

• Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

  The Lancet. Oncology 20030901

• The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.

  The Journal of endocrinology 20030901

• The binding of HIV-1 protease inhibitors to human serum proteins.

  Biophysical chemistry 20030901

• Outcomes of dual-protease inhibitor salvage therapy in human immunodeficiency virus-infected patients referred to a telephone consultation service.

  Pharmacotherapy 20030901

• Pharmacokinetic drug interactions with nevirapine.

  Journal of acquired immune deficiency syndromes (1999) 20030901

• Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20030901

• Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.

  Journal of acquired immune deficiency syndromes (1999) 20030901

• Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.

  Leukemia & lymphoma 20030901

• Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.

  AIDS patient care and STDs 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.

  AIDS clinical care 20030901

• Kaletra goes it alone.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20030901

• Virological rebound after suppression on highly active antiretroviral therapy.

  AIDS (London, England) 20030815

• The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030815

• Calpain regulates enterocyte brush border actin assembly and pathogenic Escherichia coli-mediated effacement.

  The Journal of biological chemistry 20030808

• Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity.

  Mathematical biosciences 20030801

• Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.

  The Journal of infection 20030801

• Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion.

  Journal of acquired immune deficiency syndromes (1999) 20030801

• Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

  Antiviral research 20030801

• [Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].

  Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20030801

• Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro.

  Pharmaceutical research 20030801

• Rapid assessment of P-glycoprotein inhibition and induction in vitro.

  Pharmaceutical research 20030801

• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

  Antiviral therapy 20030801

• Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

  Antiviral therapy 20030801

• Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.

  AIDS (London, England) 20030725

• Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy.

  AIDS (London, England) 20030704

• Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein?

  AIDS (London, England) 20030704

• Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models.

  International journal for parasitology 20030701

• HIV protease inhibitors acutely impair glucose-stimulated insulin release.

  Diabetes 20030701

• Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.

  International journal of antimicrobial agents 20030701

• Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.

  HIV medicine 20030701

• pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.

  AIDS research and human retroviruses 20030701

• Rapid enzymatic test for phenotypic HIV protease drug resistance.

  Biological chemistry 20030701

• Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire.

  AIDS (London, England) 20030701

• Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.

  AIDS (London, England) 20030701

• Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

  The Journal of infectious diseases 20030615

• A review of low-dose ritonavir in protease inhibitor combination therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030615

• Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.

  AIDS (London, England) 20030613

• Latrogenic nephrogenic diabetes insipidus.

  AIDS (London, England) 20030613

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• Cholelithiasis possibly induced by protease inhibitors in 3 patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz.

  Chemical & pharmaceutical bulletin 20030601

• [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20030601

• Nucleoside-free regimen tested.

  AIDS patient care and STDs 20030601

• Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

  Antiviral therapy 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.

  AIDS (London, England) 20030523

• Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.

  AIDS (London, England) 20030523

• [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].

  Deutsche medizinische Wochenschrift (1946) 20030509

• High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors.

  AIDS (London, England) 20030502

• Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.

  The Journal of antimicrobial chemotherapy 20030501

• APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.

  The Journal of antimicrobial chemotherapy 20030501

• Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line.

  Chemotherapy 20030501

• Once-a-day highly active antiretroviral therapy: a systematic review.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030501

• Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?

  Atherosclerosis 20030501

• Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

  Clinical pharmacology and therapeutics 20030501

• Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants.

  Antiviral research 20030501

• Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

  Seminars in liver disease 20030501

• Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

  AIDS patient care and STDs 20030501

• Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.

  AIDS patient care and STDs 20030501

• Preliminary CONTEXT trial results released.

  AIDS patient care and STDs 20030501

• In-vitro crystallization of indinavir in the presence of ritonavir and as a function of pH.

  The Journal of pharmacy and pharmacology 20030501

• [Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].

  MMW Fortschritte der Medizin 20030428

• [Justified hope after 4 years. Initial therapy still without resistance].

  MMW Fortschritte der Medizin 20030428

• [Results of a large randomized study: after switch to LPV/r quality of life improved].

  MMW Fortschritte der Medizin 20030428

• [A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].

  MMW Fortschritte der Medizin 20030428

• [Managing side effects. Individualized dosage makes indinavir more tolerable].

  MMW Fortschritte der Medizin 20030428

• ['Double boosting' passes the test. LPV/r plus SQV in complicated salvage situation].

  MMW Fortschritte der Medizin 20030428

• Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425

• Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.

  Journal of medicinal chemistry 20030424

• Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030415

• Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

  AIDS (London, England) 20030411

• Phase II clinical trials of Kaletra.

  AIDS (London, England) 20030411

• Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030401

• HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen.

  Journal of acquired immune deficiency syndromes (1999) 20030401

• Sildenafil does not alter nelfinavir pharmacokinetics.

  Therapeutic drug monitoring 20030401

• Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.

  The Annals of pharmacotherapy 20030401

• Liquid/liquid extraction using 96-well plate format in conjunction with hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the analysis of fluconazole in human plasma.

  Journal of pharmaceutical and biomedical analysis 20030401

• Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.

  HIV medicine 20030401

• Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.

  HIV medicine 20030401

• Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.

  Journal of clinical pharmacology 20030401

• Resistance data also presented.

  AIDS patient care and STDs 20030401

• Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.

  Xenobiotica; the fate of foreign compounds in biological systems 20030401

• [Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20030401

• An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.

  Clinical therapeutics 20030401

• Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.

  Medical mycology 20030401

• [Drug-induced seizures].

  Ugeskrift for laeger 20030331

• Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.

  AIDS (London, England) 20030328

• Determining the relative efficacy of highly active antiretroviral therapy.

  The Journal of infectious diseases 20030315

• HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

  AIDS (London, England) 20030307

• Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.

  AIDS (London, England) 20030307

• Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.

  Drug metabolism and disposition: the biological fate of chemicals 20030301

• Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20030301

• The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy.

  Expert opinion on investigational drugs 20030301

• Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

  Pediatrics 20030301

• Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20030301

• Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.

  The Journal of pharmacy and pharmacology 20030301

• Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.

  European journal of medical research 20030221

• Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.

  European journal of medical research 20030221

• Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

  The Journal of pharmacology and experimental therapeutics 20030201

• The etiology of urolithiasis in HIV infected patients.

  The Journal of urology 20030201

• Pseudo-Parkinson disease secondary to ritonavir-buspirone interaction.

  The Annals of pharmacotherapy 20030201

• HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.

  The Journal of clinical investigation 20030201

• The efficacy of lopinavir in individuals experiencing protease inhibitor failure.

  Journal of acquired immune deficiency syndromes (1999) 20030201

• Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20030201

• Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of mass spectrometry : JMS 20030201

• Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20030201

• Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers.

  British journal of clinical pharmacology 20030201

• The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030201

• SOLO trial results released.

  AIDS patient care and STDs 20030201

• A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

  Biochemistry 20030128

• Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.

  European journal of medical research 20030128

• Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.

  AIDS (London, England) 20030124

• [Fatty liver and increased serum lactate in a woman with HIV].

  Deutsche medizinische Wochenschrift (1946) 20030117

• Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

• Lopinavir/ritonavir absorption in a gastrectomized patient.

  AIDS (London, England) 20030103

• Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.

  The Journal of pharmacology and experimental therapeutics 20030101

• Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.

  The Journal of antimicrobial chemotherapy 20030101

• The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling.

  Journal of lipid research 20030101

• Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir.

  HIV clinical trials 20030101

• Protease inhibitor shown to hold HIV at undetectable levels.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20030101

• In vitro activity of potential anti-poxvirus agents.

  Antiviral research 20030101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20030101

• Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy.

  Scandinavian journal of infectious diseases 20030101

• Kidney damage reported in some tenofovir users.

  TreatmentUpdate 20030101

• Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

  CNS drugs 20030101

• Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project.

  Health and quality of life outcomes 20030101

• Saquinavir: a review of its use in boosted regimens for treating HIV infection.

  Drugs 20030101

• Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

  BMC infectious diseases 20030101

• Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy.

  HIV clinical trials 20030101

• Saquinavir/low-dose ritonavir: its use in HIV infection.

  AIDS reviews 20030101

• Tipranavir.

  Drugs 20030101

• Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease.

  Health and quality of life outcomes 20030101

• Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.

  Digestion 20030101

• Clinical pharmacokinetics of atorvastatin.

  Clinical pharmacokinetics 20030101

• The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells.

  In vitro cellular & developmental biology. Animal 20030101

• Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

  HIV clinical trials 20030101

• Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients.

  HIV clinical trials 20030101

• Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome?

  Scandinavian journal of infectious diseases 20030101

• [Development of approaches to enhancing of patient adherence to antivirus therapy in the treatment of human immunodeficiency virus infection].

  Terapevticheskii arkhiv 20030101

• Clinical vignette in antiretroviral therapy: jaundice.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20030101

• A Comparison of the Therapeutic Plan Costs in the Treatment of HIV-Positive Patients.

  Clinical drug investigation 20030101

• Response to a protease-inhibitor (ritonavir)-containing combination antiretroviral regimen in HIV-infected children.

  The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 20030101

• Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.

  Journal of acquired immune deficiency syndromes (1999) 20021215

• Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.

  Journal of acquired immune deficiency syndromes (1999) 20021215

• Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.

  Journal of molecular biology 20021206

• Diurnal variation of plasma protease inhibitor concentrations.

  AIDS (London, England) 20021206

• Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20021205

• Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus.

  Journal of medical virology 20021201

• New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.

  Bioorganic & medicinal chemistry 20021201

• Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

  International journal of antimicrobial agents 20021201

• Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.

  Cancer research 20021201

• Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives.

  Journal of molecular graphics & modelling 20021201

• Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens.

  AIDS patient care and STDs 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• Epoxyalcohol route to hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer.

  The Journal of organic chemistry 20021129

• Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

  AIDS (London, England) 20021122

• Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021115

• Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.

  Journal of pharmaceutical and biomedical analysis 20021107

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.

  Drug metabolism and disposition: the biological fate of chemicals 20021101

• Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

  Diabetes 20021101

• Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir.

  Journal of clinical pharmacology 20021101

• Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

  Cancer research 20021101

• Hydration free energy a fragmental model and drug design.

  European journal of medicinal chemistry 20021101

• Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity.

  Pharmaceutical research 20021101

• Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data.

  Pathologie-biologie 20021101

• Can HIV infection be treated successfully with a once-daily regimen?

  The AIDS reader 20021101

• Population pharmacokinetic meta-analysis with efavirenz.

  International journal of clinical pharmacology and therapeutics 20021101

• [Ergotism in a patient treated with ritonavir and ergotamine].

  Medicina clinica 20021026

• Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

  AIDS (London, England) 20021018

• Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography-mass spectrometry.

  Journal of chromatography. A 20021018

• Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20021015

• Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.

  Antimicrobial agents and chemotherapy 20021001

• Interactions between recreational drugs and antiretroviral agents.

  The Annals of pharmacotherapy 20021001

• Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.

  Therapeutic drug monitoring 20021001

• P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.

  The Journal of antimicrobial chemotherapy 20021001

• [Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].

  Enfermedades infecciosas y microbiologia clinica 20021001

• The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.

  Endocrine reviews 20021001

• HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20021001

• Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.

  Pharmacotherapy 20021001

• Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery.

  The Annals of thoracic surgery 20021001

• Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.

  HIV medicine 20021001

• Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.

  HIV medicine 20021001

• First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results.

  HIV medicine 20021001

• Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.

  HIV medicine 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome.

  Mitochondrion 20021001

• Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.

  AIDS research and human retroviruses 20020920

• Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020915

• Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020915

• The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

  AIDS (London, England) 20020906

• Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

  The Journal of infectious diseases 20020901

• The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice.

  Journal of lipid research 20020901

• The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

  British journal of clinical pharmacology 20020901

• Concentrations of protease inhibitors in cord blood after in utero exposure.

  The Pediatric infectious disease journal 20020901

• Ritonavir protects hippocampal neurons against oxidative stress-induced apoptosis.

  Neurotoxicology 20020901

• Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

  Antiviral therapy 20020901

• Generalized hair loss induced by indinavir plus ritonavir therapy.

  AIDS (London, England) 20020816

• Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020815

• Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.

  Journal of acquired immune deficiency syndromes (1999) 20020815

• Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020805

• X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

  Bioorganic & medicinal chemistry 20020801

• Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility.

  Journal of pharmaceutical sciences 20020801

• Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

  Journal of acquired immune deficiency syndromes (1999) 20020801

• Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20020801

• Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting.

  Therapeutic drug monitoring 20020801

• Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.

  Journal of clinical psychopharmacology 20020801

• Low-dose ritonavir moderately enhances nelfinavir exposure.

  Clinical pharmacology and therapeutics 20020801

• Ritonavir-associated hyperparathyroidism, osteopenia and bone pain.

  AIDS (London, England) 20020726

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715

• Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

  Biochemistry 20020709

• Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.

  Proteins 20020701

• CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20020701

• Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.

  The Journal of infectious diseases 20020701

• Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.

  Journal of medical virology 20020701

• Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases.

  Journal of acquired immune deficiency syndromes (1999) 20020701

• Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.

  Pharmaceutical research 20020701

• Increasing choices for HIV therapy.

  The New England journal of medicine 20020627

• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  The New England journal of medicine 20020627

• Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma.

  Journal of pharmaceutical and biomedical analysis 20020615

• Inhibition of HIV replication and macrophage colony-stimulating factor production in human macrophages by antiretroviral agents.

  AIDS research and human retroviruses 20020610

• Self-reported signs of lipodystrophy by persons living with HIV infection.

  International journal of STD & AIDS 20020601

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• Functional expression and localization of P-glycoprotein at the blood brain barrier.

  Microscopy research and technique 20020601

• Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast.

  Pharmacy world & science : PWS 20020601

• Hyperlipidaemia a risk factor for femoral head osteonecrosis (Legg-Calv -Perthes-like disease) in children with AIDS: case report.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20020601

• [Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].

  Anales de medicina interna (Madrid, Spain : 1984) 20020601

• Gateways to Clinical Trials. June 2002.

  Methods and findings in experimental and clinical pharmacology 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• A neutravidin-based assay for reverse transcriptase suitable for high throughput screening of retroviral activity.

  Journal of biochemistry and molecular biology 20020531

• Budesonide-induced acute hepatitis in an HIV-positive patient with ritonavir as a co-medication.

  AIDS (London, England) 20020524

• Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020515

• Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma.

  Blood 20020515

• [When nucleoside analogs cannot be tolerated. HIV therapy with booster].

  MMW Fortschritte der Medizin 20020509

• Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

  AIDS (London, England) 20020503

• Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020501

• Extrapyramidal symptoms with ritonavir/indinavir plus risperidone.

  The Annals of pharmacotherapy 20020501

• Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.

  Archives of pediatrics & adolescent medicine 20020501

• Quantification of plasma and intracellular levels of the HIV protease inhibitor ritonavir by competitive ELISA.

  Journal of immunological methods 20020501

• Male sexual dysfunction associated with antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020501

• [Crystallization and solid state properties of molecules of pharmaceutical interest].

  Annales pharmaceutiques francaises 20020501

• Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415

• Interaction between ritonavir and statins.

  The American journal of medicine 20020415

• Rhabdomyolysis due to probable interaction between simvastatin and ritonavir.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020415

• Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Ritonavir inhibition of calcium-activated neutral proteases.

  Biochemical pharmacology 20020415

• Transplacental passage of protease inhibitors at delivery.

  AIDS (London, England) 20020412

• [A plea for an individualized therapy regimen. Which is the optimal dose?].

  MMW Fortschritte der Medizin 20020409

• [After 3 years no resistance development. Protease inhibitor with staying power].

  MMW Fortschritte der Medizin 20020409

• Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401

• Subcutaneous granulomatous lesions related to ritonavir therapy in a HIV infected patient.

  International journal of STD & AIDS 20020401

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen.

  Journal of acquired immune deficiency syndromes (1999) 20020401

• Severe interaction between ritonavir and acenocoumarol.

  The Annals of pharmacotherapy 20020401

• Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.

  The Annals of pharmacotherapy 20020401

• Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

  Pediatrics 20020401

• The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.

  HIV medicine 20020401

• The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children.

  HIV medicine 20020401

• New dosing regimen approved.

  AIDS patient care and STDs 20020401

• Iatrogenic Cushing's syndrome in an HIV-infected patient treated with inhaled corticosteroids (fluticasone propionate) and low dose ritonavir enhanced PI containing regimen.

  The Journal of infection 20020401

• Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment.

  AIDS (London, England) 20020329

• Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

  AIDS (London, England) 20020329

• Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20020329

• The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

  AIDS (London, England) 20020329

• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

  AIDS (London, England) 20020308

• Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors.

  AIDS (London, England) 20020308

• FDA approves new dosing for amprenavir and ritonavir combination.

  AIDS treatment news 20020308

• [Acute coronary syndromes in patients treated with HIV protease inhibitors].

  Presse medicale (Paris, France : 1983) 20020302

• Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020301

• Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.

  Journal of virology 20020301

• Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

  The Journal of infectious diseases 20020301

• Lopinavir/ritonavir (ABT-378/r).

  Expert opinion on pharmacotherapy 20020301

• Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.

  Journal of pharmaceutical sciences 20020301

• Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.

  Pharmaceutical research 20020301

• Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.

  The Pediatric infectious disease journal 20020301

• Therapeutic drug monitoring in HIV infection: current status and future directions.

  AIDS (London, England) 20020301

• Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.

  The Southeast Asian journal of tropical medicine and public health 20020301

• Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro.

  AIDS (London, England) 20020215

• CD36 deficiency induced by antiretroviral therapy.

  AIDS (London, England) 20020215

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Journal of virology 20020201

• Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice.

  Journal of medical virology 20020201

• Role of sequencing in therapy selection.

  Journal of acquired immune deficiency syndromes (1999) 20020201

• Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20020201

• In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

  The Journal of pharmacy and pharmacology 20020201

• Drug resistance test shows encouraging results.

  AIDS alert 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• By-passing of P-glycoprotein using immunoliposomes.

  Journal of drug targeting 20020201

• Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

  AIDS (London, England) 20020125

• Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

  AIDS (London, England) 20020125

• [Advances in the domain of HIV].

  Presse medicale (Paris, France : 1983) 20020119

• Effects of antiretroviral drug combinations on the differentiation of adipocytes.

  AIDS (London, England) 20020104

• Human infection with Cryptosporidium felis: case report and literature review.

  Emerging infectious diseases 20020101

• Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.

  Journal of acquired immune deficiency syndromes (1999) 20020101

• Sexual dysfunction secondary to gemfibrozil.

  Pharmacotherapy 20020101

• Clinical pharmacology and pharmacokinetics of amprenavir.

  The Annals of pharmacotherapy 20020101

• Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

  HIV clinical trials 20020101

• The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

  Clinical pharmacology and therapeutics 20020101

• CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 20020101

• St Johns wort increases expression of P-glycoprotein: implications for drug interactions.

  British journal of clinical pharmacology 20020101

• Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.

  Acta pharmacologica Sinica 20020101

• Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children.

  Scandinavian journal of infectious diseases 20020101

• Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.

  Infection 20020101

• Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.

  Arzneimittel-Forschung 20020101

• Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

  HIV clinical trials 20020101

• Retroviral proteases.

  Genome biology 20020101

• Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.

  HIV clinical trials 20020101

• Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.

  HIV medicine 20020101

• Encouraging resistance data for Kaletra (lopinavir/ritonavir).

  The Journal of the Association of Nurses in AIDS Care : JANAC 20020101

• Saquinavir with low-dose ritonavir twice daily.

  TreatmentUpdate 20020101

• Invirase vs. Fortovase: unexpected results?

  TreatmentUpdate 20020101

• Saquinavir once daily.

  TreatmentUpdate 20020101

• Delavirdine in rescue regimens.

  TreatmentUpdate 20020101

• Kaletra (lopinavir/ritonavir).

  The Annals of pharmacotherapy 20020101

• Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.

  Antiviral chemistry & chemotherapy 20020101

• [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ].

  Therapie 20020101

• Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.

  HIV clinical trials 20020101

• The drug efflux pump MRP2: regulation of expression in physiopathological situations and by endogenous and exogenous compounds.

  Cell biology and toxicology 20020101

• Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

  Clinical pharmacokinetics 20020101

• Impact of antiretroviral regimen switches on adherence.

  HIV clinical trials 20020101

• Indinavir-induced retinoid-like effects: incidence, clinical features and management.

  Drug safety 20020101

• Reversible coma caused by risperidone-ritonavir interaction.

  Clinical neuropharmacology 20020101

• NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.

  AIDS reviews 20020101

• Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report.

  Annals of clinical microbiology and antimicrobials 20020101

• Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.

  HIV clinical trials 20020101

• [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20020101

• Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs.

  Annali dell'Istituto superiore di sanita 20020101

• Management of protease inhibitor-associated hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Ototoxicity may be associated with protease inhibitor therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215

• The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes.

  International journal of antimicrobial agents 20011201

• Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.

  British journal of pharmacology 20011201

• Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.

  Pharmaceutical research 20011201

• Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs.

  Pharmaceutical research 20011201

• Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.

  Therapeutic drug monitoring 20011201

• Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

  Antiviral therapy 20011201

• Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations.

  Antiviral therapy 20011201

• Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).

  Antiviral therapy 20011201

• The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.

  The Journal of biological chemistry 20011130

• Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy.

  Lancet (London, England) 20011124

• HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells.

  AIDS (London, England) 20011123

• Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases.

  AIDS research and human retroviruses 20011120

• Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

  The Journal of infectious diseases 20011115

• Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.

  AIDS (London, England) 20011109

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.

  Antimicrobial agents and chemotherapy 20011101

• Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy.

  Metabolism: clinical and experimental 20011101

• Lopinavir-Ritonavir: a new protease inhibitor.

  Pharmacotherapy 20011101

• Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement.

  Clinical pharmacology and therapeutics 20011101

• Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen.

  The Annals of pharmacotherapy 20011101

• Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line.

  Journal of pharmaceutical sciences 20011101

• [Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20011101

• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

  Lancet (London, England) 20011020

• HIV-protease inhibitors alter retinoic acid synthesis.

  AIDS (London, England) 20011019

• Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015

• Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.

  Journal of medicinal chemistry 20011011

• HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.

  The Journal of biological chemistry 20011005

• Functional expression of P-glycoprotein in rat brain microglia.

  The Journal of pharmacology and experimental therapeutics 20011001

• In vitro assessment of oral lipid based formulations.

  Advanced drug delivery reviews 20011001

• What's new: newly approved drugs for children.

  Pediatrics in review 20011001

• HIV-1 induction-maintenance at the lymph node level: the 'Apollo-97' Study.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors.

  European journal of pediatrics 20011001

• [Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001].

  Presse medicale (Paris, France : 1983) 20010922

• Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.

  Journal of medicinal chemistry 20010913

• Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

  Archives of internal medicine 20010910

• Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.

  The Journal of biological chemistry 20010907

• Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.

  AIDS (London, England) 20010907

• Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

  Antiviral research 20010901

• Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.

  Clinical and diagnostic laboratory immunology 20010901

• Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir.

  The Journal of antimicrobial chemotherapy 20010901

• Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.

  British journal of clinical pharmacology 20010901

• Rapid and sensitive high-performance liquid chromatographic method for the determination of ritonavir in human plasma.

  International journal of clinical pharmacology and therapeutics 20010901

• Different combinations of ritonavir-indinavir.

  TreatmentUpdate 20010901

• Searching for the right dose of ritonavir-saquinavir.

  TreatmentUpdate 20010901

• Protection against experimental autoimmune encephalomyelitis by a proteasome modulator.

  Journal of neuroimmunology 20010830

• Cerebral ergotism under treatment with ergotamine and ritonavir.

  Neurology 20010828

• Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

  Blood 20010815

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.

  Therapeutic drug monitoring 20010801

• Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.

  Therapeutic drug monitoring 20010801

• A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.

  Clinical pharmacology and therapeutics 20010801

• Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions.

  Journal of pharmaceutical sciences 20010801

• The 2nd International Workshop on Clinical Pharmacology of HIV Therapy. April 2nd-4th 2001, Noordwijk, The Netherlands.

  Expert opinion on pharmacotherapy 20010801

• P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  AIDS (London, England) 20010727

• Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.

  AIDS research and human retroviruses 20010720

• Effects of retroviral protease inhibitors on proteasome function and processing of HIV-derived MHC class I-restricted cytotoxic T lymphocyte epitopes.

  AIDS research and human retroviruses 20010720

• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy.

  Journal of chromatography. A 20010713

• 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.

  Journal of medicinal chemistry 20010705

• CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

  The British journal of ophthalmology 20010701

• A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20010701

• Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.

  Journal of acquired immune deficiency syndromes (1999) 20010701

• HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.

  FEMS immunology and medical microbiology 20010701

• Predictors of protease inhibitor-associated adverse events.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20010701

• Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.

  Human pathology 20010701

• Orofacial effects of antiretroviral therapies.

  Oral diseases 20010701

• Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

  The Journal of infectious diseases 20010615

• The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.

  Archives of biochemistry and biophysics 20010615

• Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.

  AIDS (London, England) 20010615

• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010615

• Antiretroviral approved for use in infants.

  American family physician 20010615

• Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.

  The Journal of infectious diseases 20010601

• The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20010601

• The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.

  British journal of clinical pharmacology 20010601

• The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.

  Journal of the American Dietetic Association 20010601

• Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography--tandem mass-spectrometry.

  Clinical biochemistry 20010601

• Ritonavir: an extraordinary example of conformational polymorphism.

  Pharmaceutical research 20010601

• Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.

  Antiviral therapy 20010601

• Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.

  Antiviral therapy 20010601

• Once-a-day indinavir studied.

  AIDS patient care and STDs 20010601

• Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.

  AIDS (London, England) 20010525

• Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

  AIDS (London, England) 20010525

• Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.

  AIDS (London, England) 20010525

• Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.

  AIDS (London, England) 20010525

• A potential role for interleukin-7 in T-cell homeostasis.

  Blood 20010515

• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• [Effective in HIV: dual combination with indinavir and ritonavir].

  Deutsche medizinische Wochenschrift (1946) 20010504

• Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

  AIDS (London, England) 20010504

• P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010501

• Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.

  European journal of biochemistry 20010501

• Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.

  Bioorganic & medicinal chemistry 20010501

• [HIV-HBV coinfection and the liver].

  Gastroenterologie clinique et biologique 20010501

• Resistant to everything.

  AIDS clinical care 20010501

• Acute liver failure.

  Current opinion in gastroenterology 20010501

• [Indinavir-ritonavir combination: pharmacologic results and tolerance in patients infected by HIV].

  Presse medicale (Paris, France : 1983) 20010421

• Effect of drug efficacy and the eclipse phase of the viral life cycle on estimates of HIV viral dynamic parameters.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

  Analytical biochemistry 20010415

• Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.

  Journal of chromatography. A 20010413

• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

  AIDS (London, England) 20010413

• Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.

  AIDS research and human retroviruses 20010410

• [No resistance even after 1 year. New drug combination against HIV].

  MMW Fortschritte der Medizin 20010402

• [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way].

  MMW Fortschritte der Medizin 20010402

• [Possible complication of HIV therapy. Protease inhibitor-induced femur head necrosis].

  MMW Fortschritte der Medizin 20010402

• [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].

  MMW Fortschritte der Medizin 20010402

• [An option even for patients with multiple pretreatment].

  MMW Fortschritte der Medizin 20010402

• Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation.

  Antimicrobial agents and chemotherapy 20010401

• P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

  Molecular pharmacology 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.

  Placenta 20010401

• Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

  AIDS patient care and STDs 20010401

• Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

  The Journal of infection 20010401

• Principles and practice of HIV-protease inhibitor pharmacoenhancement.

  HIV medicine 20010401

• ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.

  AIDS (London, England) 20010330

• Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.

  European journal of medical research 20010326

• Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

  AIDS (London, England) 20010309

• [HIV: a guide on management of seropositive patients].

  Presse medicale (Paris, France : 1983) 20010303

• Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010301

• Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010301

• A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy.

  Journal of acquired immune deficiency syndromes (1999) 20010301

• The safety and antiviral effect of protease inhibitors in children.

  Pharmacotherapy 20010301

• A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans.

  International journal of clinical pharmacology and therapeutics 20010301

• Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.

  The Journal of infectious diseases 20010215

• Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.

  AIDS research and human retroviruses 20010210

• Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20010201

• CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.

  Drug metabolism and disposition: the biological fate of chemicals 20010201

• Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.

  International journal of antimicrobial agents 20010201

• Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20010201

• Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.

  International journal of STD & AIDS 20010201

• [Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy].

  Annales de medecine interne 20010201

• Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient.

  Nephron 20010201

• Use of HIV protease inhibitors as pharmacoenhancers.

  The AIDS reader 20010201

• Pharmacology and clinical experience with saquinavir.

  Expert opinion on pharmacotherapy 20010201

• [Resistance to protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010201

• Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

  AIDS (London, England) 20010126

• The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.

  AIDS (London, England) 20010126

• Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

  AIDS research and human retroviruses 20010120

• Lopinavir/ritonavir: a protease inhibitor combination.

  The Medical letter on drugs and therapeutics 20010108

• ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

  AIDS (London, England) 20010105

• Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

  British journal of clinical pharmacology 20010101

• Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20010101

• Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.

  Journal of acquired immune deficiency syndromes (1999) 20010101

• Ritonavir-induced carbamazepine toxicity.

  The Annals of pharmacotherapy 20010101

• The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

  Journal of human virology 20010101

• Lopinavir/ritonavir.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.

  Scandinavian journal of infectious diseases 20010101

• Saquinavir soft gelatin capsule: a comparative safety review.

  Drug safety 20010101

• New developments in anti-HIV chemotherapy.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Clinically significant drug interactions with agents specific for migraine attacks.

  CNS drugs 20010101

• [Drug interactions with antiretroviral agents].

  Therapie 20010101

• Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy.

  The Annals of pharmacotherapy 20010101

• Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.

  Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101

• Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.

  Journal of biological regulators and homeostatic agents 20010101

• Development of HIV protease inhibitors: a survey.

  Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20010101

• Kaletra approved in Canada.

  TreatmentUpdate 20010101

• Amping amprenavir with ritonavir.

  TreatmentUpdate 20010101

• From grapefruit juice to ritonavir.

  TreatmentUpdate 20010101

• Ritonavir and indinavir one year later.

  TreatmentUpdate 20010101

• Using ritonavir with indinavir in cases of virologic failure.

  TreatmentUpdate 20010101

• Kaletra versus nelfinavir.

  TreatmentUpdate 20010101

• Human immunodeficiency virus-hepatitis C coinfection: swapping new problems for newer ones.

  Internal medicine journal 20010101

• Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.

  HIV clinical trials 20010101

• A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.

  HIV clinical trials 20010101

• The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

  HIV clinical trials 20010101

• Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.

  HIV clinical trials 20010101

• Self-reported nonadherence with antiretroviral drugs predicts persistent condition.

  HIV clinical trials 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.

  HIV clinical trials 20010101

• The use of efavirenz as a part of late rescue antiretroviral treatment.

  HIV clinical trials 20010101

• The importance of sequencing in treatment options.

  Positively aware : the monthly journal of the Test Positive Aware Network 20010101

• Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.

  Journal of enzyme inhibition 20010101

• Clinical ergotism induced by ritonavir.

  Scandinavian journal of infectious diseases 20010101

• Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.

  HIV medicine 20010101

• Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort.

  HIV medicine 20010101

• Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients.

  BMC microbiology 20010101

• Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

  HIV clinical trials 20010101

• Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women.

  HIV clinical trials 20010101

• Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia.

  Journal of clinical apheresis 20010101

• Can delavirdine substitute for ritonavir?

  TreatmentUpdate 20010101

• 'In vitro' antifungal activity of protease inhibitors.

  Mycopathologia 20010101

• New drug approvals in 2000.

  General dentistry 20010101

• In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.

  Journal of human virology 20010101

• New drugs.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20010101

• Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20001215

• Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

  Biological & pharmaceutical bulletin 20001201

• Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.

  AIDS (London, England) 20001110

• Inhibition of HIV-1 protease by a boron-modified polypeptide.

  Biochemical pharmacology 20001001

• Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

  AIDS (London, England) 20000908

• Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

  Journal of medicinal chemistry 20000907

• In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

  Antimicrobial agents and chemotherapy 20000901

• Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.

  Antimicrobial agents and chemotherapy 20000901

• BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

  Antimicrobial agents and chemotherapy 20000801

• Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.

  Journal of virology 20000801

• Potential interaction between ritonavir and carbamazepine.

  Pharmacotherapy 20000701

• Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

  Antiviral chemistry & chemotherapy 20000701

• Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.

  Bioorganic & medicinal chemistry letters 20000605

• A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

  Journal of virology 20000501

• In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

  The Journal of infectious diseases 20000501

• Protease inhibitors: current status and future prospects.

  Journal of medicinal chemistry 20000210

• In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors.

  AIDS (London, England) 20000107

• Decreased methadone effect after ritonavir initiation.

  Pharmacotherapy 20000101

• Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.

  The American journal of medicine 19991201

• Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.

  Bioorganic & medicinal chemistry letters 19991115

• Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor.

  AIDS (London, England) 19991001

• Failure of indinavir to inhibit Candida albicans in vitro.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19991001

• Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.

  Journal of medicinal chemistry 19990923

• Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.

  The Journal of biological chemistry 19990820

• In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.

  The Journal of infectious diseases 19990801

• Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient.

  The New England journal of medicine 19990603

• HE2000 shows efficacy.

  AIDS patient care and STDs 19990601

• Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990501

• [Discontinuing protease inhibitor treatment of HIV-1 patients for intolerance. Longitudinal study of 309 patients].

  Presse medicale (Paris, France : 1983) 19990227

• Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.

  The Journal of infectious diseases 19990101

• HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells.

  Journal of human virology 19990101

• Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands.

  Bioorganic & medicinal chemistry letters 19981215

• ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

  Antimicrobial agents and chemotherapy 19981201

• Lipid lowering therapy in patients with HIV infection.

  Lancet (London, England) 19981128

• [Nephrotoxicity of ritonavir].

  Presse medicale (Paris, France : 1983) 19981114

• Renal insufficiency induced by ritonavir in HIV-infected patients.

  The American journal of medicine 19981101

• Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.

  Biochemistry 19981027

• Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

  Virology 19981025

• Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.

  AIDS (London, England) 19981022

• Hepatotoxicity associated with ritonavir.

  Annals of internal medicine 19981015

• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

  Antimicrobial agents and chemotherapy 19981001

• Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.

  Chemistry & biology 19981001

• Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.

  Journal of medicinal chemistry 19980924

• In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

  Journal of virology 19980901

• Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

  The Journal of infectious diseases 19980801

• Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

  The New England journal of medicine 19980730

• Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.

  Journal of medicinal chemistry 19980618

• S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 19980601

• Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.

  Journal of virology 19980501

• Ritonavir-associated myasthenia gravis.

  Muscle & nerve 19980501

• Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.

  Journal of medicinal chemistry 19980212

• Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.

  AIDS research and human retroviruses 19980120

• Nonsymmetrically substituted cyclic urea HIV protease inhibitors.

  Journal of medicinal chemistry 19971205

• Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

  Journal of virology 19971101

• In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates.

  Antimicrobial agents and chemotherapy 19971101

• Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.

  Antiviral research 19971101

• Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.

  Biochemistry 19971007

• In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.

  The Journal of infectious diseases 19970501

• Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.

  Antimicrobial agents and chemotherapy 19970501

• Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

  Biochimica et biophysica acta 19970425

• New drugs--reports of new drugs recently approved by the FDA. Ritonavir.

  Bioorganic & medicinal chemistry 19970301

• Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.

  Journal of medicinal chemistry 19970117

• Ritonavir and renal failure.

  The New England journal of medicine 19970109

• Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.

  The Journal of biological chemistry 19961213

• Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.

  Journal of virology 19961201

• HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.

  Journal of medicinal chemistry 19961011

• Renal failure after treatment with ritonavir.

  Lancet (London, England) 19960907

• Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

  Nature medicine 19960701

• Protease inhibitors shine in triple combinations.

  AIDS alert 19960301

• A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.

  Journal of medicinal chemistry 19960119

• In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.

  Antiviral research 19960101

• Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

  AIDS research and human retroviruses 19960101

• A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

  The New England journal of medicine 19951207

• Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

  Biochemistry 19950725

• ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

  Proceedings of the National Academy of Sciences of the United States of America 19950328

• Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

  Journal of virology 19950201

• Educating the learning disabled adolescent about sexuality.

  Journal of learning disabilities 19791101